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ABSTRACT
The projects described in this dissertation revolve around the functional
consequences experienced by the transport protein for the neurotransmitter
dopamine resulting from alterations to its palmitoylation condition or exposure to
Parkinson disease-inducing transport substrates. This membrane-resident
transport protein, pragmatically termed the dopamine transporter, relocates
dopamine from extracellular areas of receptor sites of action to intracellular
sequestration; the dopamine transporter is a powerful mediator of dopamine
signaling. As such, genetic, toxicant, or chronic breakdown of dopamine
transporter function is associated with multiple psychological abnormalities.
Biomedical research has produced several pharmacotherapies for maladies like
depression, attention deficit/hyperactivity disorder, and addiction, some of which
produce their therapeutic profiles by modulating dopamine transporter function.
The potential for pharmacological manipulation of the dopamine transporter is,
however,

not

without

its

dark

side.

Dopamine’s

critical

role

in

the

neurotransmission of reward and pleasure render the dopamine transporter a
favorite target of illicit, addictive drugs of abuse like cocaine and several flavors of
amphetamine. All of these factors make intimate understanding of the many
mechanisms involved in the dopamine transporter’s function relevant not only to
mental, but also societal health. This dissertation explores aspects of dopamine
transporter mechanistic regulation which, once more thoroughly understood, may

xviii

be modified to allow finer control over transporter operation, generating novel
approaches to mental health treatment.
The

first

study

investigates

site

identification

and

functional

characterization of post-translational modification of the dopamine transporter by
a lipid moiety, palmitic acid. Palmitic acid, hexadecanoic acid in IUPAC
nomenclature, is a saturated 16 carbon fatty acid whose attachment to proteins is
termed S-palmitoylation. This lipidation process is executed by an array of
enzymes belonging to the acyl transferase class of the gene name zDHHC.
Importantly, S-palmitoylation is reversible: a protein’s palmitoylation status can
change in response to cell stimuli or the palmitoylated protein’s activation. As
palmitate is of an aliphatic nature, its attachment creates a hydrophobic protein
microenvironment around the site of its augmentation which propitiates its insertion
into likewise hydrophobic loci – usually membranes – which induces a proteinspecific functional outcome. A combination of dopamine transporter proteolysis,
site-directed mutagenesis, acyl-biotinyl exchange, surface biotinylation, and
forward and reverse dopamine transport assays implicate two N-terminal cysteine
residues as sites of palmitate incorporation, in addition to the previously analyzed
C-terminal site, and reveal a role for this lipid modification in dopamine transportermediated dopamine efflux.
The second project seeks to further understand the dopamine transporter’s
contribution to Parkinson disease. The hallmark of this disease is a loss of motor
coordination precipitated by selective death of nigro-striatal dopamine neurons and
concomitant depletion of dopamine neurotransmission in the movement planning

xix

and execution region of the brain – the striatum. The selective loss of these
neurons directly correlates with dopamine transporter expression; indeed, even
amongst dopamine neuronal pathways, the nigro-striatal fiber, which is lost to the
greatest extent of these, has the highest transporter expression. It is for this reason
the dopamine transporter has been a focus of Parkinson disease research. This
study utilizes the dopamine transporter substrates 6-hydroxydopamine and 1methyl-4-phenylpyridinium, which induce cell death through a panoply of
biochemical mechanisms and are used to generate Parkinsonian symptoms in
animal models, to probe for aberrant dopamine transporter function and posttranslational modification. This inquiry revealed that, though these compounds
induce cell death through similar mechanisms, their dopamine transporter-specific
effects are quite different. Interestingly, 1-methyl-4-phenylpyridinim is a strong
inducer of dopamine uptake downregulation and dopamine efflux, a phenomenon
now implicated in Parkinson disease onset, while 6-hydroxydopamine mitigates
this efflux event as well as attenuates transporter phosphorylation.
Overall, this dissertation argues for the existence of N-terminal
palmitoylation of the dopamine transporter, that palmitoylation is an additional
contributor to the dopamine efflux paradigm, that transporter-mediated efflux may
contribute to Parkinson disease onset, and that some of the transporter-specific
effects of 6-hydroxydopamine may be exploited to alleviate neuropsychiatric
maladies associated with aberrant dopamine efflux.

xx

CHAPTER 1
INTRODUCTION
Dopamine
Preface – The Modern Soma
In the ancient Vedic religious text, Rig Veda, is described a deity who is
both deity and ritual – the immortal and the means of immortality – Soma1. One
seeking interlocution with the Soma entity ingests the Soma plant or Soma plant
liquid extract during the ‘Soma-sacrifice’ ceremony to achieve the desired
transcendence1. The psychotropic ambrosia derived from this god/plant/libation
induces

stimulant,

hedonic,

hallucinogenic,

entactogenic,

and

euphoric

experiences and is thought to grant the participant longevity, vitality, and
resurrection2. The identity of the Soma plant described in the 9th Mandala of the
Rig Veda has long been a subject of scholarly debate3–5, yet over the epochs a
multitude of vines, herbs, and flowers has likely been used in the Soma ritual as
all the plants in question contain mind-altering compounds like ibogaine, L-DOPA,
ephedrine, tryptamines, or monoamine oxidase inhibitors6. The altar is erected, the
fire kindled, the Soma berries crushed, the celebrant exults.
Is this not, in some sense, the experience of the drug abuser? Is he not after
some form of transcendence? Some attempt, albeit misguided, to escape the
banality and disappointment of everyday life? Are there more innocuous
1

manifestations of this practice? What of the avid social media user who seeks but
is, for some reason, unable to find what he is searching for after the hours of
mindless scrolling? Is it the same exhilaration sensed at the first like of his first post
he seeks? Or, perhaps, is it the perpetual self-affirmation attained from those
glimpses into a former lover’s socially sanitized, filtered, and photo shopped faux
reality where she is still unable to hide those acne blemishes? For what is the
television watcher searching during the hours of mass consumption of vicarious
experience through his favorite streaming television dispensary? Happiness?
Maybe sought after but never achieved. Enlightenment? Surely not. What of
sports? What, exactly, is the function of ESPN? What of E! Entertainment
Television? How many human lifetimes are obliterated in trivialities and vacuous
curiosity? How much ingenuity, innovation, and intellectual and scientific
breakthrough have been expunged by visions of Harry Potter, Mickey Mouse, and
Michael Jordan? Television programming, indeed. What about the individual
overcome by ubiquitous hyper-sexualization and his concomitant descent into
depths of deviance and diminishing returns associated with sex addiction? Is the
purpose of his existence achievement of sexual gratification? Of course not, but
why does his brain insist it is so? How much culpability lies at the feet of society
and circumstance and how much at his? Or the chronic eater-of-feelings whose
brain is now wired to interpret that dust sprinkled dehydrated cardboard as food
but is completely oblivious that it is that very dust doing the wiring and the
dehydrated cardboard is anything but food?
How does a civilization’s art degenerate from Franz Schubert to Cardi B?

2

Aldous Huxley was a preeminent philosopher, author, and scientist of his
generation. In his most famous, far ahead of its time, and prophetic work, Brave
New World7, Huxley details life in a future totalitarian technocracy which maintains
absolute control through advanced social, psychological, and biological
engineering which aims to keep all citizens distracted and contented. This control
technique is typified in use by all citizens, regardless of socio-economic status, of
the perfect drug: Soma. It is described7:
“Two thousand pharmacologists and bio-chemists were
subsidized in A.P. 178… Six years later it was being produced
commercially. The perfect drug… Euphoric, narcotic, pleasantly
hallucinant… Take a holiday from reality whenever you like, and come
back without so much as a headache or a mythology… One cubic
centimetre cures ten gloomy sentiments… Now-such is progress-the
old men work, the old men copulate, the old men have no time, no
leisure from pleasure, not a moment to sit down and think- or if ever
by some unlucky chance such a crevice of time should yawn in the
solid substance of their distractions, there is always soma, delicious
soma.”

This Soma is consumed to eschew concern, negative emotion, cognitive
dissonance, and especially sentiments of rebellion and change. How does one
think, let alone imagine, beyond a matrix of inculcated pleasure-seeking? If one is
contented and saturated with creature comforts will he be able to break his
pleasure-inducing fetters? Is there any similitude between Huxley’s dystopian drug
use and a phenomenon of the modern lifestyle? It seems so: drugs of abuse8–12,
sex13–17, food18–21, video games22, television23, and social media24, all elicit
dopamine-potentiated rewarding properties and are capable of producing
addiction25–32 – a prime mover of which is dopamine (DA) neurotransmission33–35.
Activation of the DA reward pathway has achieved a coup d’état of motivation for
3

human behavior, or, more likely, a coup d’état of the DA reward pathway has
achieved dominion over human behavior. This is the modern Soma and it is of the
Brave New World category rather than the transcendent Vedic form. The former
produces somnolence while the latter is an attempted step in the journey for truth.
The sociological and anthropological impact of dopamine reward seeking
behavior is utterly mind-boggling. There are not many greater influences on human
behavior (perhaps money or religion) and the pleasure principle as the end to
which behavior is directed will increase in influence as newer thrill-inducing
technologies captivate wider swaths of youth and adult populations (television to
video games to virtual reality to what?). So, how has the archetypical instantiations
represented by Cardi B come to predominate over the Franz Schuberts? The
former is saturated with several forms of sensual appeal to the so called ‘reptilian’
brain and directs the mind’s eye toward immediate gratification (pleasure) in place
of future rewards of greater purpose to which the latter harkens. The net result of
choosing more and more of the ‘Cardi Bs’ across all sensory input manifestations
(TV, food, sex, etc.) is the detachment of purposeful action from the reward
satiation, producing rampant inaction; the release of dopamine-directed reward as
an end in and of itself. It keeps the user plumbed into the La-Z-Boy rather than
working to effect change and producing some good in the ‘real world’ and certainly
not questioning anything. And with the stunning array of new gadgets, toys,
movies, media platforms, pornography, bands, TV shows, video games, ‘news’
programs, sporting events, etc., etc., one ends up floundering in a PavlovianSkinnerian abyss of highly personalized dopamine-guided behavioral patterns.

4

When one gets a tattoo of the DA molecule, is he truly aware of how he is branding
himself? How has this come to be?
Pavlov, Skinner, Learning, Behavior, and… Advertising?
Reinforcement learning36 (RL) is a process by which learned behavior is
either supported (positive reinforcement) or opposed (negative reinforcement) by
environmental

stimuli.

Pavlovian

conditioning

(RL)37

occurs

when

an

unconditioned stimulus (US), classically a food reward, is predicted by a
conditioned stimulus (CS), classically a ringing bell, which produces a conditioned
response (CR), classically salivation, after repeated CS-US trials. This type of RL
conditions reflexive or involuntary behaviors. The Skinnerian36 advancement of
Pavlov’s paradigm was to induce a subject’s voluntary behavior in eliciting reward
or avoiding noxious stimuli. In this paradigm, the experimental subject operates on
its environment (hence ‘operant’ conditioning) such that a behavior, like lever
pressing (the lever being the environmental stimulus which cues the behavior),
produces a food reward, which, after repetition, becomes a behavior-reinforcing
stimulus pairing. The subject learns that lever pressing produces the food reward.
Thus, behavior can be conditioned through stimulus-response learning and a
subject’s voluntary and involuntary behavior can be conditioned to attain reward
and avert punishment through environmental stimuli (Figure 1).
The neurobiological mechanism by which RL occurs is activation of DA
neurons38,39. The primary neuronal DA tract activated by rewarding stimuli is the

5

Figure 1. Pavlovian and Skinnerian conditioning compared. Simple
schematic comparison of classical conditioning of a dog’s conditioned
involuntary response (panting, excitement, tail wagging) to the conditioned
stimulus (whistle) in expectation of a unconditioned stimulus (food reward) to
operant conditioning of a mouse’s voluntary response (operation of the lever)
to elicit the behavior reinforcing food reward. Image courtesy of
https://fthmb.tqn.com/eKmmGPsmUZvy7k68o36Lq1LUeHg=/1500x1000/filter
s:fill(ABEAC3,1)/2794861-classical-vs-operant-conditioning5afc42a343a10300370da76f.png, with permission.

6

mesolimbic DA pathway whose nexus is the ventral tegmental area (VTA) and
which ultimately innervates the nucleus accumbens (NAc) of the ventral
striatum40,41 (Figure 2). Rewarding stimuli activate phasic DAergic neuron
responses42 while punishments actually inhibit their firing43,44. Amazingly, after
conditioning by Pavlov’s system, activation of these DA neurons transfers from the
reception of the US to the presentation of the CS45. This process occurs through
DA coding of prediction error (PE) and determination of incentive salience. A PE
occurs when an individual’s subjective estimation about a future outcome is
incorrect, resulting in an outcome that is either greater than anticipated (positive
PE) or worse than expected (negative PE)46,47 (Figure 3). In fact, the amount of
excited quantal DA release is directly proportional to the subject’s prediction of the
reward value48,49 and probability of receiving the reward50. As more and more
stimulus-response iterations are experienced and their respective values are
coded for by DA NAc neurons, the stimulus which is associated with the greatest
DA release will achieve incentive salience, or the highest motivational value, to
which end the subject’s behavior becomes directed 51–53. Indeed, NAc DAergic
signals are essential for the attribution of incentive salience (‘wanting’), but is not
required for the hedonic impact of reward (‘liking’)34,54,55, which is mediated through
opioid56,57 and endocannabinoid58 accumbens transmission.
Though it is the primary neurological system for RL 59, the DA-mediated
attribution of incentive salience becomes more complex and individualized in
higher order species, with, quite obviously, humans being the most complex and

7

Figure 2. Major dopamine pathways in the brain. Schematic diagram of the
brain’s DA tracts. The nigrostriatal pathway originates in the substantia nigra
and innervates the striatum and coordinates movement (discussed in greater
detail in chapter III). The mesolimbic fiber runs from the VTA to the NAc and is
involved in reward. The mesocoritcal tract also begins in the VTA and
terminates in multiple regions of the prefrontal cortex and contributes to
cognitive control and emotion. The tuberoinfundibular pathway cell bodies
reside in the hypothalamus and send processes to the pituitary gland where DA
secretion
controls
prolactin
release.
Image
courtesy
of
http://medlibes.com/uploads/Screen%20shot%202010-0715%20at%2010.48.11%20PM.png, with permission.
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Figure 3. Firing of
DA
neurons
encodes
reward
prediction
error.
Reception
of
an
unexpected
rewarding
stimulus
induces burst firing of
DA neurons, positive
prediction error (top).
Application
of
a
conditioned stimulus
induces
phasic
neuron stimulation,
but the reception of
the reward does not
alter basal DA neuron
firing pattern, no
prediction
error
(middle). Conditioned
stimulus
induces
expected
neuronal
excitation, but the
absence of reward
ablates even tonic
firing of DA neurons,
negative
prediction
error
(bottom).
Adapted from ref #46,
with permission.
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individualized. Perturbations in attribution of incentive salience are associated with
two prevalent human diseases: depression can be a result of deficits of incentive
salience attribution wherein the depressed individual assigns subnormal
motivational value to rewarding tasks60–62, and addiction coincides with excessive
attribution of incentive salience to behavior which negatively affects one’s life,
producing chronic alterations to DA-mediated motivation systems63,64. It is the
usurpation of the DA-incentive salience system that results in addiction65, yet it is
also a takeover of this mechanism which marketing and advertising is hoping to
achieve – with every advertisement, all the time. The advertiser’s tactics are
sometimes subtle66–68 and sometimes overt (Figure 4)69,70, but the end result is a
ruthless, shameless attempt to subvert the target audience’s (you) incentive
salience attribution capacity – to instill, using an amalgamation of Skinnerian and
Pavlovian RL schemas71, irrational desire for a product one does not need, and,
ultimately, to habituate the purchase and use of the marketed product72. Thus an
effective advertisement (like the one in Figure 4) supplies the CS that stimulates
involuntary NAc DA signaling (the strength of which depends on the amount and
subjective significance of pleasure modalities it appeals to) in the viewer’s brain
which alters his perception of the product (reality, really) such that he values the
product higher than what it is actually worth, generating an illogical desire for its
attainment. Advertising contributes to several addiction-associated disorders
including alcoholism73, compulsive buying74, and obesity75–77. We learn by the
modern soma, we survive by the modern soma, we behave according to the
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Figure 4. How does this sell bacon cheeseburgers?!? This conditioned
stimulus (advertisement) appeals to multiple aspects of male psychology,
producing a manipulated DAergic reaction which biases the inflicted individual’s
attribution of incentive salience and subsequent behavior toward ingestion of
Carl’s Jr. rather than Burger King (probably) because….sex. What a time to be
alive!!
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modern soma, but we do not thrive on the modern soma. The ubiquity of DA
science extends from pharmacological through the sociological disciplines, and,
after analysis of our epoch by scholars of millennia to come, it will be of
anthropological and historical significance.
Synthesis, Exocytotic Release, and Receptors
In the central nervous system, DA executes numerous physiological
functions. In addition to the previously described learning and rewarding properties
of DA neurotransmission, emotion, cognition, movement, memory, and sensory
processes all involve DA signaling. Intriguingly, DA has been demonstrated to
perform peripheral functions as well: DA is synthesized and secreted by pancreatic
β-cells whereby it regulates insulin release78–80, and it is likewise produced and
released by immune cells to modulate several aspects of their function, including
cytokine synthesis and secretion81–83. DA is a catecholamine transmitter which
relates that its structure possesses a benzene ring from which project two hydroxyl
functional groups and ethylamine (Chapter 3 Figure 1). DA is synthesized from its
amino acid precursor L-Tyrosine (Tyr) which is transported across the blood brain
barrier (BBB) by large neutral amino acid transporter (LAT1)84 and enters DA
neurons. The sequential enzymatic reactions of tyrosine hydroxylase (TH) and
aromatic L-amino acid decarboxylase (AADC) cooperate to produce DA from Tyr.
TH requires tetrahydrobiopterin, iron (Fe2+) and molecular oxygen to catalyze the
rate-limiting step of DA synthesis to further hydroxylate Tyr’s aromatic ring. The
molecular product of this reaction is L-dihydroxyphenylalanine (L-DOPA) which,
like Tyr, passes the BBB via LAT1 activity84 and is therefore a standard treatment
12

for the DA-deficient disorder, Parkinson disease (PD)85. TH function is increased
by neuron depolarization-induced extracellular signal-regulated protein kinase
(ERK) and cAMP-dependent protein kinase (PKA) phosphorylation of Serine (Ser)
residues 19, 31, and 4086,87. AADC removes the carboxylic acid moiety from LDOPA’s α-carbon, creating 3,4-dihydroxyphenethylamine or dopamine (DA). DA
can be converted to norepinephrine by dopamine beta hydroxylase which can be
further modified to epinephrine by phenylethanolamine-N-methyltransferase in
neurons expressing these enzymes88. Cytosolic DA is tightly controlled as it can
transform into cytotoxic reactive oxygen species and is thus rapidly deaminated by
monoamine oxidase enzymes or methylated by catechol-o-methyl transferase89.
After synthesis, DA is sequestered into vesicles through the vesicular
membrane transport protein, vesicular monoamine transporter (VMAT2)90 (Figure
5). VMAT2 packages DA into vesicles in opposition to the DA concentration
gradient through its pairing with proton antiport congruent with the H+ gradient. Low
vesicular pH is maintained by vesicular H+-ATPase activity. Once loaded with
transmitter, vesicles undergo anterograde trafficking along microtubule filaments
by ATP-dependent kinesin function91,92. Once docked in the axon terminal ‘active
zone’, priming of the vesicle, fusion of the vesicular and plasma membranes, and
egress of the vesicle cargo is carried out by soluble N-ethylmaleimide sensitive
factor attachment protein receptor (SNARE) machinery93–95 (Figure 6). SNARE
proteins belong to two broad categories: vesicle (v)-SNAREs which are present on
granule membranes, and target (t)-SNAREs which reside in the nerve terminal
plasma membrane. Conformational adjustment of the α-helical t-SNARE syntaxin
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Figure 5. Synthesis and release of DA. DA is enzymatically generated from
L-tyrosine by sequential tyrosine hydroxylase and aromatic L-amino acid
decarboxylase activities. DA is translocated into vesicles through vesicular
monoamine transporter. DA is released into the synapse after vesicular fusion
with the axon terminal membrane. Excess cytosolic DA is catabolized by
monoamine oxidase in neurons and catechol-o-methyltransferase in
surrounding
cells.
Image
reproduced
from
https://i.pinimg.com/originals/6d/6b/60/6d6b60d62d807a077c7327bd177b216
e.jpg, with permission.
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Figure 6. Protein mechanisms in vesicular-plasma membrane fusion
and pore formation. A-B) Syntaxin conformation change recruits SNAP
interaction. C-E) VAMP proteins (synaptotagmin, synaptobrevin) interact
with the q-SNARE system which, with the aid of CA2+ forms a cis-SNARE
complex which fuses the plasma and vesicle membranes. F-G) SNAP
and NSF proteins sequentially bind to the SNARE structure. ATP
hydrolysis mediated by NSF induces conformational changes to the NSF
structure which produces spring-loaded disassembly of all involved
protein complexes. Imaged adapted from ref # 93, with permission.
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causes its HaHbHc domain to move away from its glutamine rich region which
recruits assembly of other t-SNARE α-helical proteins, such as SNAP-25. This tSNARE complex interacts with the likewise α-helical v-SNARE proteins,
synaptobrevin and synaptotagmin (Syt), forming a cis-SNARE complex. After
action potential-stimulated Ca2+ influx and Ca2+-Syt binding, this cis-SNARE
structure acts like a zipper to draw the vesicular and plasma membranes together
and provide the energy necessary for membrane fusion and pore formation 93,96,97.
Additional SNAP proteins and the N-ethylmaleimide sensitive factor (NSF)ATPase congeal to form a SNAP/SNARE/NSF 20s complex98. NSF-catalyzed ATP
hydrolysis disassembles the 20s and cis-SNARE structures99,100.
DA exocytosis occurs through this pore. Only 25-40%101,102 of the estimated
33,000103 vesicular DA molecules are released upon fusion events which allows
the neuron to more finely control transmitter release and avoid arduous vesicle
recycling tasks101. Once released into the synapse, DA interacts with its
endogenous cognate receptors to produce DA’s physiological outcomes. These
DA receptors are of 5 separate classes, all of which are members of the GPCR
superfamily and therefore have an extracellular amino-terminus, cytosolic
carboxyl-terminus, and seven α-helical transmembrane (TM) domains104.
Conventionally, the DA receptor subclasses are divided according to their
modulation of cAMP production: D1 and D5 receptors are coupled to the adenylate
cyclase (AC)-stimulating G-protein, Gαs/olf, while D2, D3, and D4 receptor subtypes
signal through Gαi/0 to inhibit AC activity; D1-type receptors stimulate protein kinase
A (PKA) while D2-type receptors blunt PKA (Figure 7). An important assimilation
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point for dopamine receptor signaling is dopamine and cAMP regulated
phosphoprotein, Mr 32 kDa (DARPP-32). PKA phosphorylates DARPP-32 at
Thr34, turning DARPP-32 into a potent inhibitor of protein phosphatase 1 which,
in turn, influences a plethora of cellular systems105,106. DARPP-32 mediates the
activity of several drugs of abuse that affect DAergic neurotransmission 107,108. It is
now known that in addition to these canonical cAMP-PKA pathways, DA receptors
signal through several cAMP-independent mechanisms including but not limited
to: transactivation of multiple receptor tyrosine kinases109–111; interaction with and
modulation of N-type calcium channel112,113 and Na+/K+ ATPase114,115 operations;
stimulation of phospholipase C116,117 through Gβγ118 and Gαq119,120 mechanisms;
coupling to β-arrestin, classically associated with receptor desensitization121, to
form scaffolds122 for kinase and phosphatase signaling processes123; and signaling
through protein kinase B to prompt glycogen synthase kinase activity124–126. DA
receptors are functionally regulated through post-translational phosphorylation127–
131

and palmitoylation132–138. After DA is released into the synapse to signal through

its target receptors, its concentration and duration in the synaptic schism is
terminated through reuptake into the presynaptic neuron via the dopamine
transporter.
The Dopamine Transporter
Structure and Mechanism of DA Transport
The dopamine transporter (DAT)139 is the an integral membrane protein
found predominantly in the perisynaptic membranes of presynaptic DA nerve
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Figure 7. Dopamine receptor effector proteins and signaling cascades.
Schematic representation of DA signaling through its cognate receptors. D1 and
D5 receptors excite AC function through Gαs/olf; D2, D3, and D4 subtypes
attenuate AC production of cAMP by Gαi. cAMP stimulates PKA which
phosphorylates numerous downstream targets, like DARPP-32, and influences
several signaling pathways and transcription factors. DA receptors have also
been shown to activate PLC through Gαq and Gβγ proteins. Image adapted from
https://medicine1journal.wordpress.com/2013/08/15/congestive-heart-failurepharmacological-approach-iii/ with permission.
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terminals and is so named for its function: transport of DA from the synaptic space
to the cytosol of the presynaptic neuron. After regulated control of vesicular DA
egress, DAT is the primary means of controlling DA homeostasis in the synapse;
thus, it regulates DA’s influence on target pre- and post-synaptic neurons. DAT
belongs to the solute carrier family 6 (SLC6)140 gene family which also includes
neurotransmitter and amino acid transporters for serotonin (5-HT), Norepinephrine
(NE), γ-aminobutyric acid (GABA), and glycine, proline, taurine, and the osmolytes
betaine and creatine with whom DAT shares high amino acid sequence homology
and structural topology139,141–143. Advancement in understanding the secondary
structure of the neurotransmitter sodium symporters (NSSs; transporters DAT,
SERT, NET) coincided with their molecular cloning144–147 and subsequent
hydropathy146,147 and topology148–150 assessments which deduced 12 α-helical
transmembrane (TM) domains, cytosolic N- and C- termini, a large, glycosylated
extracellular loop (EL) structure between α-helices III and IV, and a disulfide
bond151 within this EL (Figure 8)152. The NSSs possess approximately 600 amino
acids; the rat DAT (rDAT) isoform contains 619 residues, and the human (hDAT)
consists of 620. It wasn’t until the resolved X-ray crystal structure of the NSS
bacterial homologue leucine transporter (LeuT) that the tertiary structure of the
SLC6 family came into view142. LeuT, like the predicted NSS secondary structure,
comprises 12 α-helical TM domains and intracellular N- and C- termini. The LeuT
crystal also revealed unwound regions in TMs 1 and 6 which coordinate substrate
binding142,153, and a pseudo-symmetric inverted repeat structure wherein TMs 1-5
form a V-shape motif which is mirrored by similar, but inverted architecture of TMs
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Figure 8. Secondary structure of DAT based on the LeuT crystal
structure. Schematic representation of DAT topology. Relative position of
DAT’s 12 TM domains are shown with unwound regions as the putative
site of substrate and Na+ ion binding. Also shown are the intracellular
amino and carboxyl termini and glycosylation events on EL 2. Image
adapted from ref # 152, with permission.
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6-10142. This ‘5 + 5 inverted repeat’ motif has since been discovered in transporters
unrelated to members of the SLC6 family or LeuT154.
The drosophila melanogaster (d)DAT crystal structure was resolved in 2013
and provided further insight into DAT architecture (Figure 9)155. DAT core tertiary
structure is similar to LeuT in that TMs 1-5 and 6-10 form a 5 + 5 inverted repeat
fold inside of which TMs 1, 3, 6, 8, and 10 form a substrate permeation pathway.
This DAT crystal does, however, have several unique features. TM 12 has a kink
induced by a proline residue halfway along its α-helix which causes the portion in
the cytoplasmic plasma membrane leaflet to jut-out from the transporter. A
cholesterol molecule is wedged between TMs 1a, 5, and 7 which likely helps
maintain DAT in an outward-open structural conformation156 as it inhibits free
motion of TM 1a as DAT progresses through substrate bound and unbound
conformations157, though this cholesterol might be an artifact of the crystallization
process. The intracellular C-terminus is composed of a 2.5 turn helix and acts as
a latch through interaction with intracellular loop (IL) 1 which may play a role in
substrate transport155.
DAT-mediated DA translocation is conducted in an alternating access
mechanism (Figure 10)158. This process involves movement of the transporter
through multiple conformations initiated by substrate binding to an outward-open
conformation159,160. This outward-open conformation exposes the substrate
binding site to the extracellular solvent. After DA enters its binding pocket, Asp79
being crucial for coordination of DA’s amine group161,162, the transporter transitions
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Figure 9. X-ray crystal structure of dDAT. Tertiary structure of dDAT
locked in the outward-open conformation by the tricyclic antidepressant
nortriptyline. Displayed are the locations of the 12 TM α-helical barrels, the
cytoplasmic cap produced by the C-terminal peptide which contains a short
helical segment (blue), the bend to TM 12 produced by Pro572 tilting TM
12b away from the permeation core (purple), and a cholesterol molecule
(yellow) bound between TMs 1a, 5 and 7 where it reduces the ability of TM
1a to isomerize between its conformational states necessary for substrate
translocation. Image adapted from ref # 155, with permission.
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into an occluded position in which neither extracellular nor intracellular substratesolvent exposure occurs via movement of TMs 1b, 6a, and EL4 into the substrate
binding vestibule, forming an extracellular ‘gate’ which seals the substrate pocket
from the extracellular milieu142,157,163. The final transition from this occluded state
to the inward-open, substrate-releasing conformation is induced by movement of
TM 1a away from DAT’s core164 and breaking of the intracellular gating network
which is comprised of a salt bridge between Arg60 and Asp436 stabilized by
cation-π stacking of Arg60 and Tyr335165,166, and latching mechanisms formed by
TM1a-IL1-C-terminus interactions155. After DA is released into the cytosol, DAT
isomerizes back into the outward-open conformation for further DA translocation
events.
DAT is a secondary active transporter and as such the motive power for
‘uphill’ DA transport is supplied by movement of sodium ions down its Na+/K+ATPase-maintained concentration gradient, like other members of the NSS
family167. DAT’s substrate transport process involves simultaneous transport of
DA, two Na+ ions and one Cl- ion; DAT is, therefore, a symporter. The first Na+ ion
(Na1) stabilizes the outward-open conformation until substrate binding, and
accommodates DA binding and DAT conformational transitions during transport
rearrangements; it is coordinated by the side-chains of dDAT residues Asn49,
Ser320, and Asn352 and backbone carbonyls of Ala44 and Ser320 from TMs 1
and 6155,168–170. The second Na+ ion’s (Na2) location is accommodated by residues
from TMs 1 and 8 by peptide carbonyls from Gly42, Val45, and Leu417 and sidechain oxygens of Ser421 and Asp420; this Na+ ion also stabilizes the outward-
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open pre-substrate DAT structure, controls cation permeation of DAT, and its
release into the cytosol triggers conformational isomerization to the inward-open
pose155,169–172. The Cl- ion resides 5 Å away from the Na1 location and is
coordinated by Tyr69, Gln316, Ser320, and Ser356 from TMs 2, 6, and 7; the Clmolecule increases affinity for Na+ at the Na2 site and thus regulates inward-open
conformation probability155,172,173. The alternating access conformational pivots
occur only after the DA substrate binds to an outward-open conformation primed
by two Na+ and one Cl- co-substrates. Once DA binds, TMs 1b and 6a, with EL4,
form a ‘lid’ which seals off access to extracellular solvent. The intracellular segment
of TM 5 unwinds, granting cytosolic solvent access to the Na2 site. This event
sparks the ultimate transition of DAT to its inward-open conformation which sees
TM1a swing away from the substrate binding pocket producing solvation thereof
and the concomitant entry of DA and the Na2 sodium into the neuronal cytosol
(Figure 11)171,174,175.
Regulation
DAT function is subject to extensive control through posttranslational
modification and biding partner interactions. Rat and human DATs are
glycosylated on Asn residues of EL2176. This modification supports DA uptake
Vmax, trafficking of the transporter to the plasma membrane and its retention there,
and decreases potency of cocaine177–179. Increased DAT glycosylation has been
proposed as a mechanism which increases susceptibility to DA neuron loss
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Figure 10. Alternating access mechanism of substrate transport. The
substrate binding vestibule is exposed to extracellular solvent in the outwardopen pose (left). After substrate binds in the permeation core, the transport
protein undergoes structural rearrangements to restrict extracellular solvent
access (top). This involves TMs 1b, 6a, and EL4 in the LeuT transport process.
This occluded conformation is relieved by rearrangement of intracellular gating
and loop networks and involves ‘swinging out’ of TM 1a which exposes the
substrate binding locus to intracellular solvent into which substrate is released
– this is the inward-open conformation (right). The transporter then moves back
through the occluded pose to return to the outward-open conformation. Adapted
from ref # 158, with permission.
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Figure 11. Na+ Involvement in the neurotransmitter transport process. Na+
ions (green spheres) enter into their Na1 and Na2 sites and stabilize the
outward-open transporter conformation (1) which allows substrate to bind and
induce isomerization to the occluded formation (2). This induces closer of the
extracellular vestibule, causing TM 5i to unwind (3) and provide intracellular
access to Na2, releasing this Na+ (4). TM 1a shifts away from the protein
allowing substrate and Na+ from Na1 to enter the cytosol (5) after which the
transporter returns to the outward-open conformation (6). Image adapted from
ref # 175, with permission.
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characteristic of Parkinson’s disease by increasing DAT plasma membrane
expression180.The E3 ubiquitin ligases Nedd 4-2 and Parkin catalyze ubiquitylation
of DAT on N-terminal Lys residues 19, 27 (hDAT), and 35 which contributes to
PKC-stimulated DAT endocytosis and degradation181–183. Parkin function has been
demonstrated to support DAT function as mutant Parkin proteins, which result in
PD, fail to properly ubiquitylate improperly folded transporters184. Cholesterol
likewise aids in DAT activity as removal of this molecule results in reduced DA
transport Vmax, increased Km, loss of outward-open conformational stabilization,
Amphetamine (AMPH)-stimulated DA reverse transport (efflux), and leads to
aberrant PKC-induced downregulation156,185–187. This cholesterol-DAT interplay
contributes to DAT association with cholesterol-rich lipid raft membrane
microdomains where scaffolding of DAT-involved signaling complexes is
accomplished186.
Membrane raft and non-raft DAT networks with multiple protein partners.
The Ras-like GTPase in neurons, Rin, interacts with DAT’s C-terminus to control
endocytic processes after PKC activation188. Similarly, Flotillin-1-DAT interplay
contributes to transporter internalization as well as raft recruitment and AMPHinduced DA efflux189. The SNARE protein Syntaxin 1a (Syn1a), along with the
receptor for activated C kinase (RACK), complex with DAT to induce its
internalization through phosphorylation by PKC190. Syn1a interacts with the Nterminus of DAT by which it also blunts DA uptake, reduces transporter plasma
membrane expression, and supports AMPH-stimulated DA reverse transport191–
193.

The Lewy body aggregate protein, α-Synuclein, binds to DAT’s distal C-
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terminus where it enhances DA efflux, blunts DA uptake, and increases DATmembrane raft localization194–196. The G-protein βγ subunits physically interact
with the cytosolic carboxyl-peptide of DAT to promote DA efflux and blunt
uptake197–199. The D2 DA autoreceptor partners with the DAT at its distal Nterminus to promote DAT recycling to the surface and acutely increase DA
reuptake through PKC and extracellular signal regulated kinase (ERK)-related
mechanisms, an operation that may be perturbed in Schizophrenia200–203 (Figure
12).
Perhaps

the

most

studied

of

DAT’s

regulatory

processes

is

phosphorylation204. Kinase-potentiated phosphorylation events have been
demonstrated to exert functional control over DAT. Activation of PKC induces
reduced DA transport Vmax, enhances DA efflux parameters, and plays a role in
DAT internalization205. PKC activators like phorbol 12-myristate, 13-acetate (PMA)
and agonists for receptors coupled

to Gαq stimulate transporter

32P

incorporation206,207. Opposite of the PKC effect, ERK activity increases DAT
plasma membrane expression and DA uptake capacity201,208. Calcium-calmodulin
dependent kinase II (CAMKII) interacts with DAT C-terminally and contributes to
in vivo and heterologously expressed AMPH-induced, DAT-mediated DA efflux,
but has only been shown to phosphorylate a DAT N-terminal peptide in vitro209–211.
PKA upregulates DAT function212. DAT surface expression and function is
increased by tyrosine kinase activity213, and insulin receptor-coupled Akt2214 and
PI3K215 activities maintain DAT surface levels. Okadaic acid inhibition of their
function revealed the protein phosphatases 1 and 2a (PP1 and PP2a) act upon
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Figure 12. DAT binding partner interactions. Schematic representation of the
relative locations of DAT protein interactors and posttranslational modifications.
Pictured are the known ubiquitination, phosphorylation, and palmitoylation sites
(discussed later) as well as the interacting proteins Flotillin-1, α-synuclein, Rin,
Parkin, D2 DA receptor, and Syn1a. Image adapted from ref # 227, with
permission.
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DAT to control basal transporter phosphorylation levels 207, and of these, PP1
predominates216,217, though a direct protein-protein interaction has been
established between DAT and PP2A218.
Phosphoamino acid analysis of DAT-32PO4+ radiolabeling demonstrated
around 90% of the tracer’s incorporation occurred on Ser residues while the
residual incorporation occurred on Thr residues, with the majority of this labeling
happening on the distal N-terminus of DAT219. Ser2, Ser4, Ser7, Ser12, and Ser13
reside in a PKC consensus domain, and truncation of this peptide eliminates the
bulk of basal and stimulated

32PO

4

radiolabeling206,220. Individual Ser to Ala

mutations fail to eliminate transporter

32PO
4

incorporation, indicating multiple

phosphorylation events occur at DAT’s N-terminus. In vitro phosphorylation of the
recombinant rDAT N-terminus (NDAT) was induced by PKC at Ser4, Ser7, and
Ser13, and CAMKII phosphorylated Ser13 and PKA catalyzed phosphorylation of
Ser7216. Ser7 phosphorylation has been identified on the hDAT isoform by mass
spectrometry and this event contributes to conformational equilibrium 221. ERKcatalyzed, proline-directed phosphorylation of rDAT Thr53 has likewise been
demonstrated by mass spectrometry and requires peptide backbone isomerization
by the prolyl isomerase PIN1 for dephosphorylation216,222,223. This residue supports
both DA uptake and AMPH-stimulated reverse transport, and its phosphorylation
is stimulated by amphetamines216,223,224. DAT phosphorylation site information is
summarized in Figure 13.
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Figure 13. Phosphorylation of the dopamine transporter. Schematic
diagram of rDAT phosphorylation sites. The majority of DAT phosphorylation
occurs on the cytoplasmic rDAT N-terminus. Known phosphorylation sites,
Ser7, Ser13, and Thr53 are represented by larger blue circles. Potential Thr
and Ser phosphorylation sites are shown in purple. Other PKC Domain
residues are blue, residues of the CAMKII binding domain are green, and
Pro residues surrounding the proline-directed phosphorylation site, Thr53,
are yellow. Enzymes involved in each phosphorylation event are indicated
by solid arrows, and dashed arrows represent AMPH and PKC contribution
to each event. The orange Cys residue is the known rDAT palmitoylation
(red) site. Adapted from ref #204, with permission.
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DAT-Mediated DA Efflux
In addition to synaptic clearance of DA, an important physiological event
likewise mediated by DAT is non-vesicular release of DA, commonly known as DA
efflux. This effect is reliably induced by amphetamines and is, along with
competitive inhibition of DAT-coordinated reuptake of DA169,225, responsible for the
pharmacological and rewarding properties of AMPH and amphetamine-like
compounds226. Multiple hDAT single nucleotide polymorphisms are unstimulated
hyper-releasers of DA, a phenotype termed anomalous DA efflux (ADE), and this
characteristic is thought to contribute to disease etiology227. Several cellular and
DAT-centered mechanisms have been identified to produce DA efflux. N-terminal
phosphorylation of DAT is necessary for AMPH-induced DA efflux228, a process
which involves PKC and CAMKII activity204,229–231. This amino-terminus forms
electrostatic interactions with PIP2-enriched membranes through distal Lys
residues to propitiate DA efflux232. AMPH generates a channel-like conformation
of DAT through which quantal-like DA efflux occurs233; additionally, this channel
conformation is able to depolarize the neuron 234 which draws Na+ and Ca2+ into
the cell235 further exciting DA release phenomena236,237. DA redistribution from
vesicles by AMPH action at VMAT2 increases the cytosolic efflux-ready DA
concentration238–240. Methamphetamine (METH) produces efflux in many of the
same ways as AMPH but an additional sigma receptor functionality has been
demonstrated to contribute to METH-induction of DA reverse transport241,242.
DAT Disease Association
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Because DA signaling is vital to many important neurological processes,
maintenance of its normal transmission, a process to which proper DAT function
is necessary, is paramount for sound mental health. As such aberrant DAT
processes have been implicated in addiction, ADHD, and PD243. The DATtargeting psychostimulants cocaine, AMPH, and ecstasy (MDMA) increase DA
neurotransmission through inhibition of DA reuptake by DAT blockade (cocaine)
or substrate properties characteristic of competition for the DAT substrate binding
pocket and induction of reverse DA transport (AMPH, MDMA)244,245; thus, as they
greatly increase DA signaling in the mesocorticolimbic areas of the brain, they are
highly addictive substances246. Chronic use of these compounds begets altered
DA neuron synaptic connections and DAT surface expression247–250 which implies
drug taking (or drug taking-like behaviors) can induce neurobiological changes that
hamper the addict’s reward computation, incentive salience attribution, and
behavioral habits53,63,72.
PD results from loss of substantia nigra DA neurons which precipitates
dysfunction of coordinated movement. The DAT substrates 6-hydroxydopamine
and 1-methyl-4-phenylpyridinium are extensively used in laboratory settings to
reproduce loss of the nigrostriatal fiber to recapitulate characteristics of this
disease; thus, DAT has long been hypothesized to play a role in PD
pathology251,252. While the majority of PD cases are of unknown origin, genetic
mutations to α-synuclein and the E3 ubiquitin ligase Parkin, both DAT-interacting
proteins, are causative of two familial types of PD253. DAT mutations which
severely reduce levels of mature transporter and significantly reduce DA uptake
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capacity have been found in patients with infantile parkinsonism-dystonia152,254,255,
and an individual with comorbid early-onset PD and ADHD was discovered to have
multiple DAT amino acid polymorphisms which significantly blunt DA reuptake and
induce an ADE phenotype256. These findings suggest a role for aberrant DAT
forward and reverse transport characteristics in PD etiology.
Because attention and cognition are DA signaling-moderated processes257,
malfunctioning DAT has been hypothesized to contribute to ADHD etiology 258,259.
Indeed, the primary pharmacotherapies for ADHD are DAT-modulating
compounds; AMPH and methylphenidate, which operates akin to cocaine, act to
relieve the DAergic imbalance attributed to ADHD260–262. Multiple hDAT missense
mutations have been discovered in diagnosed individuals263,264. These rare
polymorphisms produce the amino acid substitutions Val55Ala, Arg237Gln,
Ile312Phe, Val382Ala, Asp421Asn, Ala559Val, and Arg615Cys (Figure 14)227,265.
Val55Ala, Ile312Phe, Val382Ala, and Asp421Asn display reduced DA uptake
capacity265,266, and the Arg615Cys substitution generates AMPH-insensitivity,
reduced membrane micro domain targeting, and is constitutively recycled 267. The
best-studied of these is Ala559Val. This hDAT polymorphism displays altered
trafficking and lateral membrane mobility, elevated tonic phosphorylation of its Nterminus, and an ADE phenotype which is blocked by AMPH and dependent upon
D2 DA receptors and CAMKII activity268–271. In addition, our lab has demonstrated
Ala559Val hDAT to be palmitoylation deficient (Shetty et al. unpublished study).
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Figure 14. 2D topological diagram of location of hDAT coding variants.
Yellow circles represent the relative locations of genetically produced
transporter amino acid substitutions. Ala559 resides in the exofacial barrel of
TM12 in a hydrophobic pocket generated by two Trp residues. This pocket is
likely disrupted by the bulkier Val side chain which may alter TM12, and as a
result, overall DAT conformation. Adapted from ref #227, with permission.
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S-Palmitoylation
Overview
S-acylation (also known as S-palmitoylation) is the chemical reaction of a
fatty acid (predominantly palmitate) to a target protein via enzymatic attachment of
the acid locus to the objective protein’s available cysteine sulfhydryl side chain,
producing a thioester bond (Figure 15)272. This attachment is unlike other protein
lapidating events (N-myristoylation, o-acylation, prenylation), which produce stable
covalent bonds, in that it is reversible273. This provides opportunity for the cell to
control a protein’s palmitoylation state in response to dynamic cell signaling274. The
cell generates entire enzyme systems to catalyze protein S-acylation and
deacylation: protein S-acyltransferases (PATs), also known as DHHC enzymes
(DHHCs) for the presence of a conserved Asp-His-His-Cys motif at their catalytic
domains, produces the sulfhydryl-lipid bond on the target protein, and acyl protein
thioesterases (APTs) and protein palmitoyl thioesterases (PPTs) are the primary
palmitate-removing enzymes275–277. In humans, the DHHC family of enzymes is
comprised of 23 different genes of the name zDHHC for their conserved zinc finger
Cys rich domain and DHHC tetrapeptide regions278. Structurally, these enzymes
possess four to six TM domains and, based on the recent crystal structure of
human zDHHC20, adopt a teepee-like conformation with the top just protruding
into the luminal/extracellular space and the catalytic DHHC active site residing at
the cytosol-membrane interface (Figure 16)279. An important feature of this
structure is the hydrophobic cavity that spans the active site well into the plasma
membrane; this cavity is crucial for housing the acyl group and confers acyl chain
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Figure 15. Mechanism of protein S-palmitoylation. Schematic diagram of
the S-palmitoylation reaction. The fatty acid from an acyl-CoA molecule is
covalently bound to an acceptor protein sulfhydryl to form a thioester bond. This
reaction is catalyzed by DHHC enzymes. The opposite reaction is catalyzed by
APTs or PPTs to produce both a free fatty acid and sulfhydryl group. Image
adapted from ref # 272, with permission.
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Figure 16. Structure of human DHHC20. hDHHC20 has four TM domains
(green), a cytosolic Cys-rich domain (blue) which contains the catalytic DHHC
motif and coordinates two Zn2+ ions and is comprised of multiple β-sheets and
α-helices, and a C-terminal domain which provides additional contacts with the
membrane through its hydrophobic residues. Adapted from ref #279, with
permission.
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length acceptance specificity of each DHHC279,280. DHHC PATs operate by a pingpong mechanism where the first step is an auto-acylation event followed by
transfer of the acyl group to the substrate protein281, and are themselves regulated
by palmitoylation of Cys residues outside their catalytic domains282. There are two
APT and one active PPT enzymes which belong to the metabolic serine hydrolase
superfamily, APT1, APT2, and PPT1277,283. The APT enzymes catalyze the
depalmitoylation of cytosolic palmitoyl-proteins and themselves undergo
palmitoylation to shuttle between golgi, mitochondrial, and plasma membranes 284–
286.

PPT1 depalmitoylates degrading proteins in the lysosome and experiences

dynamic palmitoylation cycling to reach the lysosomal membrane 287–290. More
recently the α/β-hydrolase domain containing protein 17 (ABHD17) family was
likewise demonstrated to catalyze depalmitoylating episodes, specifically of N-ras,
PSD-95, and microtubule-associated protein 6291–293. Though the depalmitoylases
demonstrate some substrate specificity, the relative dearth of enzymes which
perform this function indicates these enzymes have high substrate promiscuity or
the existence of as of yet undiscovered deacylating proteins272,277.
Once attached, the fatty acid confers local hydrophobicity to its substrate
peptide to produce divers, protein-specific, functional outcomes (Figure 17)294:
targeting of cytosolic proteins to plasma or organelle membranes295–298;
myristylated or farnesylated proteins can undergo palmitoylation to reinforce
membrane binding properties in a process known as kinetic trapping299–301; Sacylation contributes to protein assembly and exit from endoplasmic reticulum or
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Figure 17. Functional consequences of protein palmitoylation. Schematic
diagram of some protein-specific palmitoylation outcomes. Protein S-acylation
can exert control over protein trafficking, aggregation, degradation, assembly,
and/or oligomerization. Adapted from ref #294, with permission.
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Golgi apparatus302; it can produce protein aggregation and oligomerization 303,304;
it increases its target protein’s stability305–307; endosomal and lysosomal trafficking
which controls protein recycling or degradation290; protein membrane microdomain
affinity changes with S-acylation occurrence308,309; and S-acylation is able to
relieve TM domains of hydrophobic mismatch310. From this it follows that the
concert of S-acylation events in a cell at any given time regulate a wide variety of
cellular processes, and, extrapolating further, organ function. The biological
functions palmitoylation influences includes cell signaling311, exocytosis312,
endocytosis313,314,

metabolism315,316,

immune

system

signaling317,318,

ion

conductance319–323, and a deluge of host-pathogen interactions324–329. One can see
further evidence for this in the ever-expanding array of diseases linked to aberrant
S-acylation of important proteins330. Neuronal ceroid lipofuscinosis290,304,331,
multiple

cancers332,

Huntington’s

disease303,333,334,

schizophrenia335,336,

inflammation337, and more278,338. This hitherto underappreciated post-translational
modification has been calculated to be the fifth most abundant human posttranslational modification with approximately 1000 proteins demonstrated to be
palmitoylated to date339,340.
The Acyl-Biotinyl Exchange Assay
Acyl-biotinyl exchange (ABE) (Figure 18)341 is the primary method used in
these studies to investigate palmitoylation aspects of DAT’s nature. This technique
involves three basic steps: (1) blocking of non-acylated Cys thiol groups with Nethylmaleimide or methyl methanethiosulfonate; (2) specific chemical cleavage of
thioester bonds at neutral pH with hydroxylamine; (3) biotinylation of post41

Figure 18. The ABE method. Outline of the major steps of the ABE technique.
Free thiols are blocked by the MMTS reagent after which the sample is split into
two. One half undergoes hydroxylamine cleaveage of the thioester bond freeing
a Cys sulfhydryl group while the other half is treated with Tris buffer which does
not chemically remove palmitate from Cys thiols. A sulfhydryl-specific
biotinylation reagent accesses the once-palmitoylated thiol, and biotinylated
proteins are captured via avidin affinity chromatography. This capture does not
occur in the Tris-treated sample. Peptides are eluted and are free for detection
by SDS-PAGE and Western blotting or mass spectrometry.
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palmitoylated sulfhydryl groups with thiol-reactive biotinylation reagents and
subsequent NeutrAvidin affinity chromatography isolation. The strength of this
assay is that it is Cys-centered. This allows for perhaps greater sensitivity than
radiolabel procedures as protein-palmitate bonds are chemically severed, free
palmitate is removed, and the label is applied whereas radiolabeling requires
endogenous removal of unlabeled fatty acid and incorporation of the radiotracer 342.
This technique labels the entire cellular volume of palmitoylated proteins and,
consequently, is easily adapted to mass spectrometry proteomic techniques 330,343.
DAT Palmitoylation
rDAT and hDAT isoforms have been demonstrated to be palmitoylated in
rat brain tissue and heterologous expression systems by both metabolic
incorporation of [3H]palmitic acid and ABE techniques344. Incorporation of the
[3H]fatty acid occurs rapidly with its detection at 1 hour, indicative of rapid tonic
cycling of this modification of DAT. The irreversible PAT inhibitor, 2bromopalmitate (2BP), significantly attenuates DAT palmitoylation indicating DAT
palmitoylation is catalyzed by DHHCs. Acute 2BP treatment of rat striatal
synaptosomes produced significant reduction in DA uptake Vmax, while extended
2BP treatment times of DAT-expressing cells produces loss of full length DAT
protein and low Mr DAT fragments344. These two findings indicate palmitoylation
sustains acute DA uptake capacity and chronic control over DAT degradation. DAT
is acylated by DHHCs 2, 3, 8, 15, and 17 345. Co-expression of these PATs and
rDAT produce significantly increased DA uptake and total DAT expression. Rat
DAT possesses five cytoplasmic Cys residues predicted to be exposed to the
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aqueous environment and available for S-palmitoylation. Cys6, Cys135, Cys341,
Cys522, and Cys580 were mutated to Ala and assayed for any palmitoylation loss
by [3H]palmitic acid metabolic incorporation. Cys580Ala radiolabeling was reduced
by ~50% relative to WT while the others induced no change. This result indicates
Cys580 is a primary site of DAT palmitoylation (Figure 19, top)344,346. Cys580
resides at the cytoplasmic interface of TM12 and likely contributes to the proper
architecture of that α-helix, perhaps aiding its kink155. Cys580Ala rDAT displays
attenuated DA uptake kinetics and an increased turnover rate, indicating Cys580
modification is crucial for DA uptake capacity and DAT stability345,347. Our work has
also demonstrated DAT phosphorylation and palmitoylation mechanisms
reciprocally control each other347. Pharmacological positive or negative
manipulation, or mutational ablation of known sites, of each modification produced
the opposite effect on the corresponding modification. Thus, mutation of the known
DAT

PKC

phosphorylation

site,

Ser7,

induced

increased

transporter

palmitoylation, and the Cys580Ala substitution increased DAT phosphorylation.
Likewise, PKC activation decreased DAT palmitoylation, PKC inhibition increased
DAT palmitoylation, 2BP treatment increased DAT phosphorylation, and DHHC2
overexpression decreased DAT phosphorylation (Figure 19, bottom)346,347. That
~50% of the [3H]palmitate remains on Cys580Ala rDAT likely means incorporation
is occurring at other site(s) (probably Cys6, Cys135, Cys 341, and/or Cys 522)
undetectable by this technique which have yet to be elucidated. Mutagenesis of
other sites may induce higher tonic palmitoylation of transporter populations still
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Figure 19. Dopamine transporter palmitoylation mechanisms. Top Schematic
topological diagram of relative locations of potential DAT palmitoylation sites (orange
circles) and known palmitoylation site, Cys580 (orange circle with attached red
cylinder). Bottom DAT functional characteristics altered by its palmitoylation cycle.
DAT palmitoylation increases DA uptake Vmax and DAT stability while opposing DAT
phosphorylation. Adapted from ref #346, with permission.
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possessing Cys580. We therefore implemented alternate strategies, beginning
with ABE analysis of intracellular Cys to Ala mutations, to resolve other DAT
palmitoylation sites from background that cannot be detected by the radiolabeling
technique.
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CHAPTER 2
DAT N-TERMINAL PALMITOYLATION AND THIS MODIFICATION’S EFFECT
ON DOPAMINE EFFLUX
Abstract
The dopamine transporter (DAT) is the dopaminergic neuron plasma
membrane transport protein responsible for recollection of synaptic dopamine (DA)
into the neuron after stimuli-induced transmitter release. DA signaling is
responsible for a panoply of physiological consequences, and, as the primary
conduit for DA entry into eponymous neurons, DAT is one of the most popular
targets of legal and illegal chemical agents aiming to modulate DA signaling.
Malfunctioning DATs are thought to contribute to a host of neurological maladies
including bi-polar disorder, attention deficit/hyperactivity disorder (ADHD),
addiction, and Parkinson disease. DAT operation is precisely controlled through
protein interactors and post-translational modifications including phosphorylation,
glycosylation, ubiquitination, and, of importance here, S-palmitoylation – the labile,
enzymatic union of cysteine sulfhydryl moieties with the fatty acid palmitate via a
thioester linkage. S-palmitoylation conveys protein-specific functions which can
include protein oligomerization, membrane micro domain localization, protein
maturation, and alleviating transmembrane domain hydrophobic mismatch. DAT
palmitoylation was previously discovered at rat (r)DAT Cys580 and modification of
this residue acutely increases DA uptake Vmax without altering DAT surface
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expression and opposes long-term DAT degradation. As the enzymatic processes
of S-palmitoylation is primarily thought to occur on intracellularly accessible
cysteines, Cys to Ala mutants of each intracellular rDAT cysteine residue (6, 135,
341, 522, and 580) were assessed for its S-palmitoylation phenotype by the acylbiotinyl exchange (ABE) method. This process revealed an ~50% loss of
palmitoylation detection in the Cys580Ala mutant alone, a result almost identical
to the previous study utilizing incorporation of radiolabeled fatty acid. The
remaining radiolabel and ABE signals imply the presence of one or more
palmitoylation sites undetectable by these protocols. Subsequently, the alternate
sites of rDAT S-palmitoylation were probed by utilizing a combination of multiplesite Cys to Ala mutagenesis, Asp-N and CNBr proteolytic peptide mapping of
endogenous and heterologously expressed rDATs in conjunction with ABE
analyses. These methodologies revealed Cys6 and, surprisingly, the exoplasmic
Cys90 as the likely secondarily acylated rDAT sites. These residues were then
assessed for functional relevance by surface biotinylation, DA transport saturation
analyses, and reverse DA transport (efflux) assays. Palmitoylation of Cys6 residue
may invoke tethering of the cytosolic NH2-terminus of rDAT to the plasma
membrane and this Cys residue was shown to support DAT-mediated DA efflux.
Cys90 acylation may aid DAT endosomal retention and substrate reuptake as the
Ala90 mutant displays increased surface populations and decreased apparent DA
affinity. As DAT S-palmitoylation supports forward and reverse transport
processes, therapeutic alteration of this DAT modification may alleviate DATinvolved disease burden.
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Introduction
Cognition, movement, fear generalization, reinforcement learning, and, as
a result, behavior are mammalian functions mediated in the central nervous
system by the neurotransmitter dopamine (DA)42,65,244,348–350. As DA contributes to
these vital processes, its maintenance at a proper equilibrium is essential for
individual health, and divergence from healthy DA homeostasis is hypothesized to
contribute

to

the

mental disorders attention-deficit/hyperactivity disorder

(ADHD)351, Parkinson disease352, and schizophrenia353. Licit therapeutic strategies
target the properties of DA flux262, and abuse of these properties by illicit drug use,
and even excess video game play22,26, greatly increase the likelihood of addiction
disorders10. It follows, then, that fine-tuned regulation of synaptic DA concentration
is essential to well-being. After exocytotic transmitter release, DA signaling is
primarily controlled through its removal from the perisynaptic space via the
presynaptic plasmalemmal dopamine transporter (DAT) into the cytoplasm of the
expressing neuron139. DAT is a member of the sodium and chloride dependent
solute carrier 6 family of neurotransmitter transporters140 and is the molecular
target of several therapeutic agents and drugs of abuse which manipulate DAT
properties to alter synaptic DA concentration354,355.
A large body of work has demonstrated DAT function to be precisely
regulated by trafficking, post translational modification, and binding partner
mechanisms227, and much of this regulation occurs at DAT’s cytosolic N-terminus.
Control over DAT endocytosis and lysosomal degradation is exerted by
ubiquitination of three lysines on DAT’s N-terminus183, a process stimulated by
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PKC activation182. The human DAT (hDAT) associates with the anionic
phospholipid phosphatidylinositol (4,5)-bisphosphate (PIP2) through distal Nterminal lysine residues, which alters hDAT stimulant interaction232.

Several

proteins bind to N-terminal regions of DAT to modulate DAT function: the DA D2
autoreceptor binds N-terminally on DAT leading to the recruitment of additional
DATs to the plasma membrane, increasing DA uptake200; the soluble Nethylmaleimide-sensitive factor attachment receptor (SNARE) protein syntaxin 1A
networks with the first 33 residues of DAT which reduces forward DA transport and
promotes DA transport (efflux)191,193; and multiple kinases phosphorylate DAT on
its N-terminus356.
Striatal rDAT was demonstrated to be phosphorylated on N-terminal
residues by aminopeptidase instigated loss of [32P]radiolabel219. At the distal Nterminus resides a protein kinase C (PKC) binding domain. Activation of this kinase
significantly elevates transporter phosphorylation207,206, blunts DA uptake
velocity357, redistributes DATs away from the plasma membrane358, and
phosphorylates an N-terminal DAT peptide (NDAT) at Ser4, Ser7, and Ser13 in
vitro221. Proline-guided phosphorylation occurs on rNDAT216 through extracellular
signal-related kinase (ERK) action at rDAT Thr53223; a process which is sensitive
to psychostimulant activity and supports DA uptake and efflux359. Additionally, the
human (h)DAT N-terminus undergoes phosphorylation at Ser and Thr residues221
including Thr48360,361. This N-terminal DAT phosphorylation pattern is essential for
induction of DA efflux228,362, and pharmacologic activation of DAT-mediated
reverse transport coincides with phosphorylation of this DAT locus204.
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Our lab has demonstrated DAT to be lipid-modified through the Spalmitoylation process344. S-palmitoylation is the enzymatic addition of one of a
species of long chain saturated fatty acids, predominately palmitate, to sulfhydryl
functional groups of cysteine residues creating a chemically labile thioester
bond294. This process is catalyzed by the zDHHC gene family of palmitoyl
acyltransferases (PATs)278 and reversed by two separate thioesterase families:
palmitoyl protein thioesterases (PPTs) are lysosomal-resident enzymes which
hydrolyze fatty acid-protein thioester linkages during protein degradation287; and
acyl protein thioesterases (APTs) are cytoplasmic thioesterase enzymes363.
Palmitoylation increases the affinity of lipidated protein micro domains for the
hydrophobic interior of an intracellular membrane, inducing substrate-subjective
functional outcomes which can include: localizing the modified protein to a target
membrane micro domain; trafficking the protein to recycling endosomes or to
lysosomes; maturation of protein in the endoplasmic reticulum; alleviating
hydrophobic mismatch of transmembrane α-helical structures; changing the profile
of protein interactome interactors; and, ultimately, modulation of the function of the
acylated protein294. The initial study on rDAT palmitoylation identified Cys580,
which resides at the cytoplasmic interface of transmembrane domain (TM) 12, as
the primary DAT palmitoylation site344. Mutation of this Cys residue induced
fragmentation of the protein, demonstrating acylation of this residue antagonizes
transporter degradation; additionally, loss of Cys580 palmitoylation suppressed
DA transport Vmax347.
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The first report on DAT palmitoylation did not exclude the occurrence of this
modification on residues other than Cys580344, perhaps due to the limitations of
the methodology used. More recently, a reciprocal coordination between DAT
phosphorylation and palmitoylation was discovered to modulate DAT operation347.
Through mutagenesis and pharmacological means, it was shown that when DAT
phosphorylation

increases

palmitoylation

decreases;

alternatively,

when

phosphorylation decreases palmitoylation increases. The aim of this study was to
probe for the existence of rDAT palmitoylation sites separate from Cys580 in native
tissue and heterologous expression systems. We then analyze Ala mutations of
the novel DAT palmitoylation sites for DA uptake kinetic parameters and assess
the influence general cellular palmitoylation, and DAT-specific palmitoylation, exert
over DAT-mediated DA efflux.
Results
Acyl-Biotinyl Exchange Analysis of Cys to Ala Point Mutant Palmitoylation
Our previous study identified Cys580 as a major DAT palmitoylation site
using metabolic radiolabeling with [3H]palmitate. Our results suggested this
method may have been inadequate to delineate a second, lower-stoichiometric,
site if the incorporation of the radiolabeled fatty acid is indistinguishable from
background labeling. To overcome this potential limitation, we employed the acylbiotin exchange (ABE) protocol341 which, due to increased availability of oncepalmitoylated Cys residues via hydroxylamine (NH2OH)-induced liberation of the
fatty acid from the sulfhydryl functional group of Cys residues, produces higher
sensitivity342,364. This technique was used to delineate from background the effect
52

of mutational alteration of the five DAT intracellular Cys residues to determine the
presence of DAT palmitoylation sites in addition to Cys580.
However, the ABE technique yielded results akin to our previous study
(Figure 1): Cys580 is the major rDAT palmitoylation site, and removal of this site
reduces DAT palmitoylation to ~50% (*p<0.05 Cys580 versus WT, n=8), with no
discernable S-palmitoylation loss associated with Cys to Ala ablation of the other
potential sites (p>0.05 for Δ21, Cys135Ala, Cys341Ala, and Cys522Ala versus
WT, n=3 or more independent experiments). These results were nearly identical
to the radiolabeling study; the incomplete loss of Cys580Ala ABE readout again
indicates additional palmitoylation events on DAT, but the mutational loss of these
additional sites may induce over-palmitoylation of Cys580 in these transporter
populations.
Palmitoylation of Single Intracellular Cys rDATs
To resolve palmitoylation events which may occur at lower stoichiometry
than Cys580 on WT rDATs, all intracellular Cys residues were mutated to Ala save
one which was studied for the occurrence of DAT palmitoylation events at that
particular cysteine via ABE (Figure 2). This methodology revealed Cys6 as a PAT
substrate as rDAT populations possessing only Cys6 produced significantly
greater ABE signal above rDATs possessing only intracellular Cys135, Cys341, or
Cys522 (##p<0.01 Cys6 versus Cys135, Cys341, and Cys522). The Cys6 readout
was similar to that of rDATs with only Cys580; therefore, this approach confirmed
Cys580 as a DAT palmitoylation site. Here Cys6, like Cys580, was significantly
less palmitoylated than WT (***p<0.001 Cys6 versus WT n=8; ***p<0.001
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Figure 1. Palmitoylation levels of WT and mutant rDATs measured
by ABE. Membranes isolated from LLCPK1 cells expressing WT or Cys
mutant DATs were subjected to ABE to determine palmitoylation levels.
Upper Panels: ABE DAT levels normalized to Total DAT levels (middle
panels). Samples were subjected to SDS-PAGE and immunobloting
using MAb 16. Bottom Panel: Quantification of palmitoylation intensity
normalized to total DAT levels (means ± SE of 3 or more independent
experiments). C580A *p < 0.05 relative to WT, ANOVA with Dunnett’s
post hoc test. These experiments confirm Cys580 as an rDAT
palmitoylation site but were unable to distinguish any other palmitoylation
sites of perhaps lesser abundance.
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Figure 2. ABE analysis of WT and multiple Cys to Ala mutants of rDAT.
Mutants are named such that the number represents the only cysteine
remaining on the cytosolic portion of rDAT, e.g. ‘580’ is
Cys522/341/135/6Ala, leaving only Cys580 available to intracellular Spalmitoylation. Membranes isolated from LLCPK1 cells expressing the
indicated DAT were subjected to ABE. These experiments confirm Cys580
as an rDAT palmitoylation site and support Cys 6 as an additional site of
the fatty acid incorporation. n=3 for 522, 341, 135; n=8 for WT, 580, and 6.
*** p<0.001 for 580 and 6 vs WT, ### p<0.001 for 580 vs 522, 341, 135, and
##p<0.01 for 6 vs 522, 341, 135 (means ± S.E.). Statistical analyses
performed by ANOVA with Tukey’s post hoc test.
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Cys580 versus WT, n=8). That the Cys580 mutant did not possess palmitoylation
signatures like WT is further evidence supporting the existence of extra-580
palmitoylation sites; this set of experiments impugns Cys6 as that site.
Palmitoylation of DATs with or without the Putative Palmitoylation Sites
To strengthen this finding, we compared palmitoylation signals of rDAT
mutants

possessing

only

the

two

putative

palmitoylation

sites

(Cys135/341/522Ala) with an rDAT mutant population possessing the three
intracellular Cys residues and without the two that are palmitoylated (Cys6/580Ala)
(Figure 3). The results show palmitoylation of Cys135/341/522Ala to be at WT
levels (p>0.05 Cys135/341/522Ala versus WT, n=3) while Cys6/580Ala ABE
signals are at background levels (**p<0.01 Cys6/580Ala versus WT, n=3). This
further supports Cys 6 as a second rat DAT palmitoylation site.
In Vivo Palmitoylation of the rDAT N-terminal Peptide
To determine if rDAT is palmitoylated on its N-terminus in vivo, an approach
similar to previous photoaffinity labeling with subsequent proteolytic peptide
mapping of the transporter was implemented365–368. However, in these
experiments the photoaffinity tagging was replaced with the ABE process.
Enzymatic and chemical proteolysis of DATs isolated from rat striatum were
subjected to the ABE process. The first approach utilized Asp-N; this enzyme
selectively cleaves peptide bonds on the N-terminal side of aspartic acid residues
and has been shown to generate a DAT peptide of approximately 19 kDa by
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Figure 3. Palmitoylation analysis of mutant DATs containing only the
Cys residues suspected of being palmitoylated or containing all Cys
residues except the suspected palmitoylation sites. Indicated mutants
were subjected to ABE as described previously. Data are presented as %
WT control. n=3, 103.90 ± 7.80 p>0.05 for C135/314/522A versus rDATs
(mean ± S.E.), and ** p<0.05 for C6/580A versus WT (mean ± S.E.).
Statistical analyses were performed by ANOVA with Tukey’s post hoc test.
These results further support both Cys580 and Cys6 as palmitoylation sites
as DATs possessing only these two intracellular Cys residues have WT
level palmitoylation signatures.
[FJ1]
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ASP-N proteolysis at Asp174, a peptide which is detected by a monoclonal DAT
antibody against an N-terminal epitope (MAb16)369(Figure 4).

Synaptosomal

preparations from excised rat striatal tissue were treated with 1µg/mL Asp-N in SP
buffer for 45 minutes at 25oC (control samples were incubated in SP alone) after
which the samples underwent the ABE protocol. After isolation, digestion, ABE
purification, and immunoblot detection with MAb16, a Western blotting signal of
~19 kDa emerged (Figure 5). This peptide is the N-terminus of rDAT (residues 1174) and, because it was isolated by ABE, is modified by S-palmitoylation. This is
the first demonstration of N-terminal rDAT palmitoylation in vivo. This portion of
rDAT’s N-terminus contains both Cys135 and Cys6, and the Asp-N-ABE protocol
is unable to distinguish between S-palmitoylation at Cys6 and Cys135.
Cyanogen Bromide (CNBr) Digestion and ABE Analysis of the rDAT Nterminus
To further delineate if this in vivo N-terminal rDAT palmitoylation event
occurs at Cys6 or Cys135, CNBr chemical proteolysis with subsequent ABE was
utilized. CNBr cleaves peptide bonds C-terminally to methionine residues. CNBr
selectively hydrolyzes DAT proximal to methionine residues (106, 111, 116) in the
second transmembrane α-helix, generating a DAT N-terminal peptide of an
approximate 11 kDa molecular weight366(Figure 6) detectable by MAb16 Western
blotting. Importantly, this peptide does not include Cys135. Synaptosomes were
prepared from extracted rat striatum and treated with 100 µL of 70% formic acid
with or without 1M CNBr for 1 hour at 25oC in the dark followed by ABE analysis
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Figure 4. Asp-N schematic proteolytic profile of rDAT. Schematic diagram
of the expanded membrane topology of DAT with 12 TMDs and intracellularly
facing N- and C-termini. Vertical stacks of amino acids (blue) represent the 12
α-helical membrane spanning domains. The extracellularly available Asp
residues are highlighted in mauve. The known sites of glycosylation (black
branched sticks), phosphorylation within the PKC-domain containing Ser7 (blue
circle) and relative sites of potential S-palmitoylation (orange circles) are
shown. The C-terminal helix (yellow, FREKLAYA) is also shown, and is the
epitope for the C-20 antibody. Asp-N proteolysis of rDAT will generate a 19 kDa
peptide which can be visualized after immunoblotting with MAb16 and a 36 kDa
peptide visible after immunoblotting with C-20.
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M

AP

Figure 5. Asp-N proteolysis of rat striatal synaptosomes and subsequent
detection of palmitoylated rDAT N-terminus by ABE. Synaptosomes were
isolated from rat striatal brain tissue. Synaptosomes were digested with 1 μg/mL
Asp-N in SP buffer for 45 minutes at 25oC while control samples were incubated
in SP alone under otherwise identical conditions. Digested synaptosomes were
subjected to ABE. SDS-PAGE, and immunoblotting with MAb 16 revealed the
presence of an ~19 kDa N-terminal palmitoylated fragment. ‘M’ arrow indicates
mature DAT, and ‘AP’ arrow indicates Asp-N-generated DAT peptide whose
presence in the NH2OH ABE lane indicates N-terminal DAT palmitoylation. This
acylation event likely occurs at Cys6 and/or Cys135. This procedure is unable to
distinguish between these two sites.
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Figure 6. Depiction of N-terminal rDAT displaying N-terminal
methionine residues, the primary aspartic acid cleavage site by AspN, and relative locations of intracellular cysteines potentially
accessible for S-palmitoylation. Methionine residues are in black. The
green residues on the N-terminus represent the epitope for anti-rDAT
primary antibody MAb16. Cleavage with Asp-N at Asp174 (large red
residue) produces an ~ 19-kDa N-terminal peptide containing the epitope
for MAb 16, Cys6 and Cys135 as seen in Figure 6. CNBr digestion at
Mets 106, 111, or 116 in transmembrane domain 2 would generate the
~11-kDa N-terminal DAT fragment seen in Figure 7.
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(Figure 7). This experiment demonstrates the N-terminus of DAT remains
palmitoylated in the absence of Cys135 – implicating Cys6 as the likely site of this
modification. This, in combination with the preceding findings (Figures 1-3),
supports Cys6 as an rDAT S-palmitoylation site and likely rules out this event
occurring at Cys135.
CNBr Proteolytic Mapping of Cys to Ala rDATs Expressed in LLCPK1 Cells
To confirm the in vivo proteolytic peptide mapping-ABE results, the same
set of experiments performed on striatal rDAT were implemented on WT, Cys6Ala,
and Cys135Ala rDATs. Plasma membrane fractions of LLCPK 1 cells stably
expressing each of the aforementioned DATs were isolated and treated with 1M
CNBr in 70% formic acid. Control samples were treated with formic acid alone to
control for fragmentation induced by acid hydrolysis. After 1 hour incubation in the
dark, the samples were subjected to the ABE process and palmitoylated DAT
peptides were detected by MAb16 immunoblotting (Figure 8). The ~11 kDa
palmitoylated DAT peptide presented in both the WT and Cys135Ala rDATs, which
was expected, but also the Cys6Ala rDATs, which was not anticipated. This result
suggests either the presence of additional N-terminal palmitoylation events, or
non-sulfhydryl binding of the sulfhydryl-specific biotinylating reagent. The more
likely answer is an additional lipidation event, though the only other Cys amino acid
resident to the N-terminal peptide generated from CNBr chemical fragmentation is
Cys90, which resides on the extracellular surface of transmembrane domain 1.
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[FJ3]

M

CP

Figure 7. CNBr digestion of rat striatal synaptosomes and subsequent
detection of palmitoylated rDAT N-terminus by ABE. Synaptosomes were
prepared from extracted rat striatum and treated with 100 µL of 70% formic acid
with or without 1 M CNBr for 1 hour at 25oC in the dark. Digested synaptosomes
were then subjected to ABE as described above and palmitoylated peptides
were detected by SDS-PAGE and immunoblot analysis with Mab 16. ‘M’ arrow
indicates mature DAT, and ‘CP’ arrow indicates CNBr-generated DAT peptide
whose presence in the NH2OH ABE lane indicates N-terminal DAT
palmitoylation, most likely at Cys 6.
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Figure 8. CNBr digestion of WT, Cys6Ala, Cys135Ala rDATs in LLCPK1
cells. LLCPK1 cells stably expressing the indicated rDAT were subjected to
CNBr chemical fragmentation at a concentration of 1M CNBr in water and
formic acid (CNBr ‘+’ lanes) or water and formic acid alone (CNBr ‘-‘ lanes)
for 1 h at ambient temperature in the dark. Reactions were terminated with
900 μL of water and lyophilized. Final pellets were solubilized in 4SB buffer
and subjected to ABE analysis and immunoblotting with MAb16. ‘M’ arrow
indicates mature DAT, and ‘CP’ arrow indicates CNBr-generated DAT
peptide. Presence of a CP in the C6A lane implies additional N-terminal DAT
palmitoylation events on this peptide which may occour on the only other
Cys residue, 90.
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Analysis of Cys90 Palmitoylation
Cys90Ala rDAT cDNA was generated and the protein was transiently
produced in LLCPK1 cells for assay by ABE (Figure 9). These experiments
demonstrate Cys90 to undergo S-acylation as the Cys90Ala rDAT ABE signature
was significantly reduced versus WT (0.96 ± 0.05 versus 1.34 ± 0.13 ABE DAT to
total DAT ratio,* p<0.05). This is only a modest reduction in palmitoylation, which
is expected as the palmitoylation substrates Cys580 and Cys6 are still present in
this DAT population; however, Cys90 may be acylated at higher stoichiometric
levels than Cys6 as the loss in Cys90Ala palmitoylation is detectable by ABE alone
while the Cys6Ala loss of palmitoylation is not. This Cys residue is known to be
highly reactive to MTS reagents370,371 and reactive oxygen species of DA orthoquinone372 which alter DA binding properties of DAT. Palmitoylation of Cys90
would be remarkable for multiple reasons. This result would represent, to our
knowledge, the first known extracellular palmitoylation event. The application of
the lipid to Cys90 would likely occur co-translationally in the ER while the majority
of palmitoylating events occur post-translationally in the Golgi298,373. Though it may
be reversible, re-palmitoylation likely does not occur once DAT is presented at the
plasma membrane as the acyltransferase machinery capable of re-applying
palmitate resides within the cell301.
Surface Expression Analysis of Palmitoylation-Deficient rDATs
The palmitoylation of Cys6 or Cys90 may serve different functions in DAT
regulation than palmitoylation of Cys580, which, in stably expressing heterologous
expression systems, supports DA uptake Vmax and opposes DAT
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Figure 9. Palmitoylation characterization of Cys90Ala rDAT. WT or
Cys90Ala rDATs were transiently transfected into LLCPK1 cells and ~36
h later were collected and plasma membrane isolation was performed.
The samples were then subjected to the ABE protocol and
palmitoylated DATs were detected by Western blotting with MAb 16.
0.96 ± 0.05 versus 1.34 ± 0.13 ABE DAT to total DAT ratio,* p<0.05 n=7
(mean ± S.E.M.) Statistical analyses were performed by Student’s t test.
This result S-palmitoylation may occur on Cys90.

66

degradation344. To determine the functional outcomes of Cys6 and Cys90
palmitoylation, Cys6Ala, Cys6/580Ala, and Cys90Ala rDATs were analyzed for
surface expression and DA uptake saturation kinetics.
The Cys580ala stably expressed in LLCPK1 cells displayed acute functional
alterations which were not precipitated by a loss of plasma membrane
transporters. Here we tested all the palmitoylation-deficient mutants for differential
surface expression patterns by cell surface biotinylation analysis after transient
transfection in LLCPK1 cells (Figure 10). The Cys580Ala rDAT has unaltered
surface characteristics (Figure 10b) (n=3, 0.94 ± 0.06 versus 1.18 ± 0.14 surface
to total DAT ratio, p>0.05) compared to WT rDAT. The same holds true for both
Cys6Ala (Figure 10a) (n=3, 0.96 ± 0.06 versus 1.02 ± 0.04 surface to total DAT
ratio, p>0.05) and Cys6/580Ala (Figure 10c) (n=7, 1.02 ± 0.03 versus 1.06 ± 0.07
surface to total DAT ratio, p>0.05); however, the Cys90Ala rDAT (Figure 10d) (n=5,
1.05 ± 0.03 versus 0.95 ± 0.02 surface to total DAT ratio, *p<0.05) displayed
elevated surface transporter levels relative to WT rDAT. The increase in surface
expression may not be due to loss of a lipidating event at Cys90, but rather the
loss of a reactive Cys. An alternative is the lipidation of Cys90 keeps this population
of DATs in an endosomal pool where they can be acted upon by PPTs in the event
increased DA uptake capacity is required by the cell; e.g. post-action potential DA
exocytosis - the result of the Ala90 rDAT would be less endosomal retention and
increased plasma membrane transporters.
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Figure 10. Surface biotinylation analysis of Cys to Ala rDATs’ surface
expression. WT, Cys6Ala, Cys580Ala, Cys6/580Ala, or Cys90Ala rDAT were
transiently transfected in LLCPK1 cells ~36 h prior to surface biotinylation analyses.
A): Cys6Ala versus WT n=3, 0.96 ± 0.06 versus 1.02 ± 0.04 surface to total DAT
ratio, p>0.05; B): Cys580Ala versus WT, n=3, 0.94 ± 0.06 versus 1.18 ± 0.14 surface
to total DAT ratio, p>0.05. C): Cys6/580Ala versus WT, n=7, 1.02 ± 0.03 versus
1.06 ± 0.07 surface to total DAT ratio, p>0.05. D): Cys90Ala versus WT, n=5, 1.05
± 0.03 versus 0.95 ± 0.02 surface to total DAT ratio, * p<0.05. (mean ± S.E.M.).
These results indicate unchanged plasma membrane populations in Cys6Ala,
Cys580Ala, and Cys6/580Ala populations while mutational lalteration of Cys90 to
Ala induces increased DAT surface populations. This effect may be due to loss of
Cys90 palmitoylation.
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DA Uptake Saturation Kinetics of Palmitoylation Deficient rDATs
To further examine the functional outcomes that loss of palmitoylation
confers upon DAT, [3H]DA saturation transport studies were performed on
Cys6Ala, Cys580Ala, Cys6/580Ala, and Cys90Ala rDATs transiently expressed in
LLCPK1 cells. Figures 11-14 detail the surface normalized Michelis-Menten
saturation curves and kinetic parameters (Km and Vmax) reflecting the DA transport
kinetics of these rDATs. Cys6Ala rDAT (Km = 1.63 ± 0.24 versus 2.09 ± 0.68,
p>0.05 µM; Vmax = 165.8 ± 7.8 versus 186.7 ± 27.6 pmol/min/mg, p>0.05) (Figure
11), like Cys6/580Ala rDAT(Km = 2.19 ± 0.14 versus 1.80 ± 0.15 µM, p>0.05; Vmax
= 137.0 ± 24.4 versus 129.3 ± 19.0 pmol/min/mg, p>0.05) (Figure 13), displays
unaltered uptake kinetics relative to WT; transiently generated Cys580Ala (Figure
12) harbors different kinetics than our stable Cys580Ala LLCPK1 line, exhibiting a
significantly larger Km for DA than WT (2.43 ± 0.19 versus 1.62 ± 0.16 µM, *p<0.05)
and no statistical change in its maximal uptake velocity (254.3 ± 61.9 versus 143.0
± 27.8 pmol/min/mg, p>0.05). Interestingly, Cys90Ala rDAT is also characterized
by an increase Km for DA compared to WT (Figure 14) (2.86 ± 0.40 versus 1.50 ±
0.24 µM, * p<0.05) with no detectable change in uptake velocity (126.4 ± 20.43
versus 140.6 ± 9.29 pmol/min/mg, p>0.05). These results are summarized in Table
1.
These studies further explored the role DAT palmitoylation sites contribute
to the DA reuptake process. Though they did not reveal a significant contribution
of these sites to maximal velocity of DA transport, which is contrary to our previous
characterization of the stably expressed Cys580Ala transporter, they did
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Figure 11. Saturation analyses of Cys6Ala rDAT. LLCPK1 cells transiently
transfected ~36 h with WT or Cys6Ala rDAT cDNA before analysis for their
respective DA uptake kinetic characteristics. Upper panel: is a MichaelisMenten graph displaying surface normalized [3H]DA saturation analyses with
increasing DA concentrations (0.32-20 µM). The mean uptake values ± S.E. of
four independent experiments are shown. Bottom left: histogram represents
Michaelis-Menten constant for DA uptake saturation experiments n=4, Km =
1.63 ± 0.24 versus 2.09 ± 0.68, p>0.05 µM (mean ± S.E.M.). Bottom right: The
histogram shows Vmax values for surface normalized DA uptake saturation
experiments n=4, Vmax = 165.8 ± 7.8 versus 186.7 ± 27.6 pmol/min/mg, p>0.05
(mean ± S.E.M.). Statistical analyses were performed by Student’s t-test.
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Figure 12. Saturation analyses of Cys580Ala rDAT. LLCPK1 cells transiently
transfected ~36 h with WT or Cys580Ala rDAT cDNA before analysis for their
respective DA uptake kinetic characteristics. Upper Panel: Michaelis-Menten
graph representing surface normalized [3H]DA saturation analyses with
increasing DA concentrations (0.32-20 µM). The mean uptake values ± S.E. of
three independent experiments are shown. Bottom Left: Histogram
representing the Michaelis-Menten constant (Km) for DA uptake saturation
experiments n=3, 2.43 ± 0.19 versus 1.62 ± 0.16 µM, *, p<.05 C580A versus
WT (mean ± S.E.M.). Bottom Right: The right histogram displays Vmax values
for surface normalized DA uptake saturation experiments n=3, 254.3 ± 61.9
versus 143.0 ± 27.8 pmol/min/mg, p>0.05. (mean ± S.E.M.). Statistical
analyses were performed by Student’s t-test.
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Figure 13. Saturation analyses of Cys6/580Ala rDAT. LLCPK1 cells
transiently transfected ~36 h with WT or Cys6/580Ala rDAT cDNA before
analysis for their respective DA uptake kinetic characteristics. Upper Panel:
Michaelis-Menten plots of surface normalized [3H]DA saturation analyses in
increasing DA concentrations (0.32-20 µM). The mean uptake values ± S.E.
of seven independent experiments are shown. Bottom Left: Histogram
representing Michaelis-Menten constant (Km) for DA uptake saturation
experiments n=7, Km = 2.19 ± 0.14 versus 1.80 ± 0.15 µM, p>0.05 (mean ±
S.E.M.). Bottom Right: The histogram shows Vmax values for surface
normalized DA uptake saturation experiments n=7, 137.0 ± 24.4 versus
129.3 ± 19.0 pmol/min/mg, p>0.05 (mean ± S.E.M.). Statistical analyses
were performed by Student’s t-test.
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Figure 14. Saturation analyses of Cys90Ala rDAT. LLCPK1 cells transiently
transfected ~36 hours with WT or Cys90Ala rDAT cDNA before analysis for
their respective DA uptake kinetic characteristics. Upper panel is surface
normalized [3H]DA saturation analysis with increasing DA concentrations (0.3220 µM). The mean uptake values ± S.E. of four independent experiments are
shown. Bottom left panel is a histogram representing the Michaelis-Menten
constant (Km) for DA uptake saturation experiments n=4 2.86 ± 0.40 versus
1.50 ± 0.24 µM, *p<0.05. The bottom right panel is a histogram showing Vmax
values for surface normalized DA uptake saturation experiments n=4, 126.4 ±
20.43 versus 140.6 ± 9.29 pmol/min/mg, p>0.05. Statistical analyses were
performed by Student’s t-test.
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rDAT Line:

Km (µM)

Vmax (pmol/min/mg)

Cys6Ala

1.63 ± 0.24

165.8 ± 7.8

Cys580Ala

2.43 ± 0.19*

254.3 ± 61.9

Cys6/580Ala

2.19 ± 0.14

137.0 ± 24.4

Cys90Ala

2.86 ± 0.40*

126.4 ± 20.43

Table 1. Summary of palmitoylation deficient rDATs DA transport kinetics
versus WT. Cys6Ala: Km = 1.63 ± 0.24 versus 2.09 ± 0.68, p>0.05 µM; Vmax =
165.8 ± 7.8 versus 186.7 ± 27.6 pmol/min/mg, p>0.05. Cys580Ala: 2.43 ± 0.19
versus 1.62 ± 0.16 µM, *p<0.05; 254.3 ± 61.9 versus 143.0 ± 27.8 pmol/min/mg,
p>0.05. Cys6/580Ala: Km = 2.19 ± 0.14 versus 1.80 ± 0.15 µM, p>0.05; Vmax =
137.0 ± 24.4 versus 129.3 ± 19.0 pmol/min/mg, p>0.05. Cys90Ala: 2.86 ± 0.40
versus 1.50 ± 0.24 µM, * p<0.05; 126.4 ± 20.43 versus 140.6 ± 9.29
pmol/min/mg, p>0.05. Statistical analyses were performed by Student’s t-test
of means ± S.E.
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reveal that the apparent affinities for DA of two of the transporter types (Cys580Ala
and Cys90Ala) were significantly increased – visualized by the significant increase
in their respective Michaelis-Menten constants. To determine how the relative
contribution of these DAT palmitoylation sites and the cellular palmitoylation micro
environment contribute to DA transport, these DAT palmitoylation site mutants
were treated with the irreversible acyltransferase inhibitor 2-bromopalmitate
(2BP)374,375 and analyzed for DAT functional outcomes.
Global Palmitoylation Inhibition with 2BP Effect on DA Uptake
2BP was initially demonstrated to reduce synaptosomal DAT-mediated DA
uptake via decreasing DAT palmitoylation344. Here, LLCPK1 cells expressing each
of the transiently produced Cys -> Ala DAT mutants were pre-incubated with 7.5
µM 2BP for 90 minutes at 37oC and 5% CO2 prior to DA uptake with 3 µM DA
containing the 10 nM [[FJ4]3H]DA tracer for 30 minutes in a 37oC water bath.
Subsequently, these cells were lysed with 1% Tx-100 for 20 min at RT and the
contents were collected and analyzed for radioactivity by scintillation counting
(Figure 15).
The results of these experiments suggest a synergistic relationship between
DAT palmitoylation and global palmitoylation events. The WT transporter exhibited
the largest DA uptake downregulation by 2BP which, as all its potential
palmitoylation sites remain intact, stands to reason (Figure 15a) (52.33 ± 9.28 WT
treated versus WT control, **p<0.01, n=3). The Cys6Ala (Figure 15b) and
Cys580Ala DATs (Figure 15c) experienced similar downregulation patterns

75

A)

B)

D)

C)

Figure 15. 2BP downregulation of DA uptake decreases with
palmitoylation-deficient rDATs. Cells transiently producing WT,
Cys6Ala, or Cys580Ala rDATs for ~36 hours were incubated with 7.5 µM
2BP for 90 min at 37oC and 5% CO2 prior to [3H]DA uptake analysis. DA
uptake data are presented as %control 52.33 ± 9.28 WT treated versus
WT control, **p<0.01, n=3. 74.05 ± 5.82 Cys6Ala treated versus Cys6Ala
control, **p<0.01, n=6. 68.63 ± 10.89 Cys580Ala treated versus
Cys580Ala control, *p<0.05, n=4. 80.83 ± 4.97 Cys6/580Ala treated
versus Cys6/580Ala control, *p<0.05, n=3. Statistical analyses were
performed by Student’s t-test of mean ± S.E. These results indicate
mutational ablation of rDAT palmitoylation sites reduces 2BP efficiency
in reducing DAT-mediated DA uptake.
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(74.05 ± 5.82 Cys6Ala treated versus Cys6Ala control, **p<0.01, n=6; 68.63 ±
10.89 Cys580Ala treated versus Cys580Ala control, *p<0.05, n=4). The loss of the
single palmitoylation site reduced the 2BP-induced DAT down regulatory effect
without completely abating it. The Cys6/580Ala DATs were even further resistant
to 2BP induced DAT down-regulation (80.83 ± 4.97 Cys6/580Ala treated versus
Cys6/580Ala control, *p<0.05, n=3) (Figure 15d). The Cys90Ala rDATs have yet
to be tested by this methodology. Eliminating the palmitate-accepting residues
from DAT attenuated the 2BP precipitated loss of DA uptake in an almost
stoichiometric manner, as individual loss-of-palmitoylation-site rDATs display less
reuptake loss than WT but more than the double site mutant (Figure 16). The
double palmitoylation site mutant, however, still undergoes significant 2BPpromoted reuptake loss, implicating S-palmitoylation events on Cys90 or within the
DAT interactome playing a role in stabilizing DAT function; i.e. syntaxin 1a is an
acyl-protein 376,377 whose interaction with DAT modulates DA reuptake. Though the
effect protein S-acylation has on this interaction has yet to be studied, syntaxin 1a
palmitoylation could either induce or inhibit its DAT interaction, rendering it an
iteration of a non-DAT palmitoylation event affecting DAT function.
Palmitoylation Deficient rDATs Display Altered DA efflux
Understanding the DA efflux phenomenon is of paramount importance to
DAT-targeted pharmaceutical interventions for psychiatric disorders, particularly
ADHD378,379. Indeed, nonsynonymous hDAT single nucleotide polymorphisms
exhibiting phenotypic aberrant DA release have been associated with ADHD380
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Figure 16. Significant correlation between 2BP-induced DAT
downregulation and number of DAT palmitoylation sites. A Pearson
correlation coefficient of 0.9570 indicates the efficiency of 2BP in limiting
DAT-mediated DA uptake is strongly correlated to the number of
palmitoylation sites present on DAT.

78

and Parkinsonism256. This DA export process is pharmacologically induced by DAT
substrates like AMPH226,381 and other AMPH congeners382. While many distinct
molecular mechanisms integrate at DAT to contribute to DAT-mediated reverse
DA transport233,237,240, N-terminal phosphorylation of the transporter is perhaps the
best-known229. As DAT phosphorylation contributes to efflux and has a reciprocal
interplay with DAT palmitoylation, DAT palmitoylation may exert influence over
DAT-mediated basal and AMPH-stimulated DA efflux mechanisms.
The palmitoylation site Cys to Ala rDATs were subjected to the biochemical
efflux assay. This process entails: DAT forward transport to ‘load’ the cells with a
DA mixture containing a [3H]DA radiotracer in KRH; washout of free radiolabel on
ice with 4oC KRH; addition of efflux buffer (KRH alone for basal or KRH with 10 µM
AMPH for stimulated efflux); collection of efflux buffer after 1 minute; lysis and
collection of uptake control cells; analysis of all collected lysates and supernatants
for radioactivity. Data are presented as % internal [3H]DA which is derived from
basal or AMPH treated supernatant counts divided by corresponding uptake
control counts then multiplied by 100. The palmitoylation deficient rDATs were
transiently transfected into LLCPK1 cells and compared to WT for differences in
both basal and/or 10µM AMPH-induced DA efflux (Figure 17). The Cys6Ala rDAT
mutation (Figure 17a) produced an inhibition of both basal and AMPH-generated
efflux (**p<0.01 C6A basal versus WT basal n=5; *p<0.05, C6A AMPH versus WT
AMPH n=5). The Cys580Ala rDAT (Figure 17b) displays no significant change in
basal DA release (p>0.05 Cys580Ala basal versus WT basal, n=4) but does
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Figure 17. Cys6 and Cys580 impose opposite effects on DA reverse
transport. [3H]DA efflux was analyzed by our biochemical reverse transport
assay. Data are expressed as % internal [3H]DA. 100% internal DA was
determined by scintillation counting of lysate from loaded cells which received
no efflux buffer. C6A: **p<0.01 C6A Basal versus WT Basal n=5; *p<0.05, C6A
AMPH versus WT AMPH n=5. C580A: p>0.05 Cys580Ala Basal versus WT
Basal, n=4; *p<0.05 Cys580Ala AMPH versus WT AMPH, n=4. C6/580A: p>0.05
Cys6/580Ala Basal versus WT Basal; p>0.05 Cys6/580Ala AMPH versus WT
AMPH, n=3. p>0.05 Cys90Ala Basal versus WT Basal; p>0.05 Cys90Ala AMPH
versus WT AMPH, n=4. Statistical analyses were performed by ANOVA with
Tukey’s post hoc test of mean ± S. E. These results indicate Cys6 acylation
events may support the DA efflux paradigm while Cys580 palmitoylation may
oppose it.
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potentiate AMPH-induced release (*p<0.05 Cys580Ala AMPH versus WT AMPH,
n=4), and both Cys90Ala (p>0.05 Cys90Ala basal versus WT basal; p>0.05
Cys90Ala AMPH versus WT AMPH, n=4) and Cys6/580Ala rDATs presented no
alterations to either basal or AMPH-stimulated DA efflux. (p>0.05 Cys6/580Ala
basal versus WT basal; p>0.05 Cys6/580Ala AMPH versus WT AMPH, n=3).
These data demonstrate that elimination of rDAT palmitoylation sites does
indeed affect the DAT-mediated DA release mechanism; losing Cys6 results in
ablated efflux patterns while mutation of Cys580 slightly, though not statistically
significantly, induced increased basal DA efflux and statistically enlarged AMPHinduced release. Interestingly, the combination mutant, Cys6/580Ala rDAT,
displayed neither altered basal nor altered AMPH DA efflux relative to WT,
alleviating both Ala6 and Ala580 rDAT efflux phenotypes (Figure 17c). Cys90Ala
rDAT also has unchanged basal and AMPH-triggered DA release, this, combined
with its Km and surface anomalies, suggest a palmitoylation event at Cys90 may
contribute to DAT trafficking and stabilization of a TM domain vital for DA uptake.
Global Palmitoylation Inhibition by 2BP Effect on DA Efflux
Ala580 rDATs have elevated basal phosphorylation, and treating
synaptosomes with 2BP generates increased whole protein phosphorylation of
native rDAT347. This information, along with the data from the previous study
(Figure 17), lend credence to the idea that both DAT palmitoylation and the cellular
palmitoylome cooperate in coordinating the DAT-mediated DA efflux mechanism.
To further explore this cooperativity, LLCPK1 cells expressing WT or one of the
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palmitoylation deficient rDATs were incubated with 7.5µM 2BP for 90 minutes in
KRH prior to analysis for DA efflux (Figure 18).
Induction of DA efflux by 10 µM AMPH from the WT transporter was
potentiated by treatment with 2BP (Figure 18a) (**p<0.01 WT 2BP AMPH versus
WT AMPH, n=5), and basal 2BP-stimulated efflux levels approach higher levels
than control basal though not yet statistically significant (p>0.05 WT 2BP basal
versus WT basal, n=5). However, 2BP basal levels are also not statistically
different than control AMPH-stimulated efflux (p>0.05 WT 2BP basal versus WT
AMPH, n=5) suggesting further experiments may demonstrate 2BP to generate
AMPH-like DA efflux. Ala6 rDATs (Figure 18b) also display greater AMPH-induced
efflux after 2BP treatment than its control AMPH counterpart (**p<0.01 C6A 2BP
AMPH versus C6A AMPH, n=6) and this mutant exhibited no alteration to basal
efflux levels (p>0.05 C6A 2BP basal versus C6A basal, n=6). The Cys580Ala
(Figure 18c) mutation does not result in altered basal or AMPH-stimulated DA
efflux after 2BP treatment (p>0.05 C580A 2BP Basal versus C580A basal, n=5;
p>0.05 C580A 2BP AMPH versus C580A AMPH, n=5). Likewise, the Cys6/580Ala
rDATs (Figure 18d) display DA efflux signatures which are unaffected by 2BP
pretreatment (p>0.05 C6/580A 2BP Basal versus WT Basal, n=3; p>0.05 C6/580A
2BP AMPH versus C6/580A AMPH, n=3). Cys90Ala rDAT has yet to be analyzed
by this methodology.
Discussion
These studies demonstrate DAT thioacylation may occur at multiple sites
distinct from Cys580, which is the site previously identified in WT transporters.
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Figure 18. 2BP affects DA efflux. [3H]DA efflux was analyzed by our
biochemical reverse transport assay. Cells transiently expressing either
WT, Cys6Ala, or Cys580Ala rDATs were incubated with 7.5µM 2BP for 90
min at 37oC and 5% CO2 after which DA reverse transport assays were
conducted. WT: p>0.05 WT 2BP Basal versus WT Basal, n=5; **p<0.01
WT 2BP AMPH versus WT AMPH, n=5. C6A: p>0.05 C6A 2BP basal
versus C6A Basal, n=6; **p<0.01 C6A 2BP AMPH versus C6A AMPH,
n=6. C580A: p>0.05 C580A 2BP Basal versus C580A basal, n=5; p>0.05
C580A 2BP AMPH versus C580A AMPH, n=5. C6/580A: p>0.05 C6/580A
2BP Basal versus WT Basal, n=3; p>0.05 C6/580A 2BP AMPH versus
C6/580A AMPH, n=3. Statistical analyses were performed by ANOVA with
Tukey’s post hoc test of means ± S.E.
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The evidence provided identifies Cys6, located on DAT’s distal N-terminus, and
Cys90, nestled amidst the head groups of the exofacial PM leaflet atop DAT TM1,
as the likely additional sites of this modification. This report also details the DA
transport kinetic impact resultant from ablation of these acylated residues, surface
transporter population vicissitudes, and the regulation of DA efflux exerted by DAT
palmitoylation in particular, as well as palmitoylation in general. These results echo
and expand upon previous DAT palmitoylation reports344,347: homeostasis of DAT
and cellular palmitoylation events are crucial for synaptic DA homeostasis.
To understand the impact post translational modifications exert upon their
modified protein, it is vital to understand where they occur. Initial DAT
palmitoylation site exploration344 utilized bulk [3H]palmitate incorporation into Cys
mutant DATs and elucidated Cys580 of rDAT as the major locus of radiolabel
incorporation. This method was unable to eliminate the presence of other sites of
DAT thioacylation as a significant amount of residual Cys580Ala radiolabeling
remained. Unfortunately, the additional palmitoylation locations were also not
readily discoverable by ABE (Figure 1), a procedure used for its more rapid
repeatability (days versus weeks/months) and increased sensitivity342, of single
Cys residue point mutations (Cys90, due to its location, was not considered at this
time). Several different biochemical approaches were then necessary. Initially, all
Cys residues were changed to Ala save one to discern if the single remaining
intracellular Cys is a PAT substrate. Palmitoylation analysis by ABE of these DAT
mutants identified Cys6 as a palmitoylation site – at least when no other
intracellular Cys residues are available for this modification (Figure 2). Importantly,
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this methodology also demonstrated Cys580 as a palmitoylation site. Figure 3
demonstrates ABE of the combination Cys6/580 rDAT mutant displays ABE
signatures near rDATs possessing only Cys135, Cys341, or Cys522 (Figure 2),
while DATs with these two sites and lacking the other three intracellular Cys
residues (Cys135/341/522Ala) presents WT-level palmitoylation. These results
rule out Cys135, 341, and 522 as palmitoylation sites and implicate Cys6 in
addition to Cys580 as a site for this modification. The loss of Cys6 not resulting in
reduced palmitoylated DAT signatures is troubling, though a possible explanation
is the transporters lacking this residue undergo increased acylation of Cys580 or
other residues.
To strengthen the mutagenesis data, in vivo determination of N-terminal
DAT palmitoylation occurring at distinct primary sequence loci was made. This was
achieved through enzymatic and chemical DAT fragmentation and subsequent
ABE purification of the palmitoylated peptides. The protocols for these experiments
were derived from previous studies on site localization of binding of photoaffinity
ligands to the DA permeation pathway of DAT 366–368,383. The result was an
amalgam of proteolysis, ABE, and epitope-specific immunoblotting techniques.
This protocol was first applied with Asp-N, use of which generates an
approximately 19 kDa molecular weight rDAT peptide which is readily detected by
immunoblotting with an antibody against an N-terminal DAT antigen369. This multistep palmitoylated peptide isolation procedure demonstrated that in vivo DAT
palmitoylation occurs at regions other than the C-terminus (Cys580) and the
occurrence is likely Cys135, Cys6, or least likely, Cys90 (Figures 4 & 5). CNBr
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chemical proteolysis of DAT occurs predominantly at the methionine cluster in TM2
and produces a peptide lacking Cys135 (Figure 6)366–368,383. This procedure
produced a palmitoylated DAT peptide of approximately 11 kDa representing Cys6
as the likely palmitoylated residue (Figure 7); the composite of this result and the
mutagenesis results effectively eliminate Cys135 as a DAT palmitoylation site.
The CNBr fragmentation/ABE process was next applied to Cys6Ala and
Cys135Ala rDATs expressed in LLCPK1 cells (Figure 8), and the result was
surprising: the Cys6Ala rDAT still harbored a palmitoylated N-terminus. This is
most likely due to an additional palmitoylated residue, likely Cys90, in this peptide.
ABE analysis of Cys90Ala rDATs displayed significantly reduced ABE readout than
the WT transporter (Figure 9). The fractional values of Cys90Ala (0.96 ± 0.05)
compared to WT (1.34 ± 0.13) imply this DAT mutant maintains around 70% WT
palmitoylation. This is a lower stoichiometric level than Cys580 and, as the two
experiments testing Cys580Ala acylation only removed ~50% of the signal, leaves
room for the possibility of additional palmitoylated residues – like Cys6.
Surface biotinylation assays were used to probe for alterations to
transporter PM population changes which would allude to altered trafficking
patterns provoked by loss of a palmitoylation site (Figure 10). The initial DAT
palmitoylation study described no surface alterations upon Cys580 mutation or
2BP treatment though chronic palmitoylation inhibition resulted in expedited DAT
degradation344. Here, the Ala6, Ala580, and Ala6/580 rDATs exhibit steady-state
PM levels akin to the WT form; surprisingly, Ala90 rDAT shows increased surface
transporter levels. The uptake kinetic data demonstrate unaltered DA saturation
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transport kinetics for Cys6Ala (Figure 11) and Cys6/580Ala (Figure 13). The
mutation of the Cys90 (Figure 14) and Cys580 (Figure 12) both generated
increased Km relative to WT. No mutation generated significant alterations to
maximal DA uptake velocity. These data demonstrate DA reuptake parameters are
dependent upon lapidating events at certain residues, but not others. These
experiments were conducted via transient induction of the full length DATs which
may explain the Cys580 result differing from the data obtained from stablyexpressing cell lines347. Acute translation and modification of the DAT protein may
vary between tissue, cell line, and protein production procedure.
The magnitude of 2BP-induced down-regulation of DA transport decreased
linearly with loss

of

palmitoylated Cys residues (Figures 15 & 16).

WT>Cys580Ala>Cys6Ala>Cys6/580Ala. This stands to reason as 2BP would
produce less DAT-subjective effects as less DAT-lipidation events are occurring.
The remaining 2BP-induced down-regulation of the Cys6/580Ala potentially results
from loss of Cys90 palmitoylation or reduced protein-protein interactions which are
propitiated by palmitoylating events. These analyses should be performed on both
Cys90Ala rDAT and the triple combination Cys6/90/580Ala rDAT.
The

DAT

substrate

AMPH384

which

stimulates

N-terminal

DAT

phosphorylation229 and interacts with vesicular monoamine transporters385 is a
powerful inducer of DA efflux. Palmitoylation deficient rDAT mutants exhibited
different AMPH-induced efflux patterns. A Cys6 palmitoylation event seems to
support efflux as loss of this residue incurs ablated basal and AMPH induced
release, while Cys580 palmitoylation events oppose efflux as elimination of this
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Cys potentiates AMPH responsiveness. Global and DAT-specific palmitoylation
was examined further by 2BP inhibition of the global palmitoylation process.
AMPH-stimulation of DA release was potentiated by 2BP in the WT and Cys6Ala
transporters and no basal increase of DA efflux was seen in any of the transporter
populations.
The rDAT palmitoylation site detection studies revealed Cys6 and Cys90 as
potential additional loci of this modification. Palmitoylation of these residues would
generate interesting structural and functional consequences. Fatty acid
attachment to Cys6 of DAT’s distal N-terminus would likely result in the tethering
of this peptide to membranous structures in proximity to it. Multiple transmembrane
proteins undergo acylation of their NH2 termini: Phospholemman requires
palmitoylation of N-terminal Cys residues 40 and 42 to blunt Na+-K+-ATPase
activity386; The ATP-binding cassette transporters A1387 and G1388 require
thioacylation of their NH2 domains for PM localization and cholesterol efflux onto
their target lipoproteins. Tethering of DAT’s N-terminus was previously reported as
being mediated by interactions with PIP2389,390 potentiating AMPH-induced DA
efflux232, a characteristic shared with SERT391, though SERT-PIP2 interplay is not
coordinated through its NH2 domain. The palmitoylation of Cys6 may operate
synergistically with PIP2 to strengthen DAT’s N-terminal interaction with the PM,
similar to the ‘kinetic trapping’392 phenomenon in which one lipid modification
(frequently N-myristoylation or prenylation) weakly increases the target protein’s
hydrophobicity enough to produce transient membrane interactions with DHHC
populated membranes to further lipidate the protein, creating stronger membrane
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affinity. This ‘kinetic trapping’ process has been documented to affect the function
of several peripheral membrane proteins393–396. Indeed, Cys6Ala rDATs display
reduced basal and AMPH-induced efflux (Figure 17a), a phenotype similar to DAT
interaction with PIP2 depleted membranes232,389 (summarized in Figure 19). Cys6
acylation would also likely impact NH2-terminus interacting proteins; interactions
between syntaxin 1a, dopamine D2 receptor, ubiquitin ligases, and protein kinases
may be contingent upon or sterically inhibited by Cys6 palmitoylation. The
neighboring amino acid, Ser7, is a phosphorylated residue, and one expects Cys6
acylation to have significant implications for the phosphorylation status of Ser7, a
scenario brought into clearer focus by the recent insight of the reciprocal
relationship between DAT phosphorylation and palmitoylation 347. It is interesting to
speculate that palmitoylation is an additional DAT N-terminal post-translational
modification coordinating the protein’s function in a ‘barcoding’ fashion analogous
to diverse GPCR phosphorylation patterns activating different signaling, protein
interaction, or endocytic outcomes397. Multiple proteins experience reciprocal
palmitoylation and ubiquitination305,329. A DAT post-translational modification
interplay has been demonstrated between phosphorylation-palmitoylation
crosstalk347, and alluded to between DAT phosphorylation-ubiquitination398 where
PKC activators induce enhanced DAT ubiquitination and degradation183,182, though
these studies do not demonstrate concomitant PKC phosphorylation and
ubiquitination of DAT. Cys6 palmitoylation may modulate both DAT ubiquitination
and phosphorylation, creating another layer of detail in the picture of fine-tuned
signaling assimilating at DAT’s NH2 peptide, marking it with phosphorylation,
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Efflux
Figure 19. Schematic of Cys6 palmitoylation tethering DAT’s Nterminus to the plasma membrane. Cys6 palmitoylation would likely
tether DAT’s N-terminal peptide to the plasma membrane. This
tethering event may aid the DAT-mediated DA efflux process.
Palmitoylation of this residue may also contribute to Lys3 and Lys5’s
interaction with PIP2 phosphlipids as well as increase the likelihood of
Syn1a interaction with the DAT N-terminus – both events which
likewise increase DAT-mediated DA efflux.
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ubiquitination, and now palmitoylation; an image which is also likely affected by
cellular machinery cycling the palmitoylation status of Cys90.
Cys90 thioesterification would likewise generate interesting outcomes.
These suggest Cys90 to be an S-palmitoylation substrate (figure 9), Cys90Ala
rDATs to have increased surface presence (Figure 10d), and increased Km for DA
(Figure 14). The location of this residue precluded its inclusion into the initial
acylation site exploration experiments as it is located on the exoplasmic leaflet of
the PM. This location renders the possibility of S-palmitoylation on plasma
membrane Cys90 being reversible unlikely, though a portion of the PPT enzymes
are secreted399,400 so removal of the synapse-side palmitate is possible, but its readdition is unlikely. This, coupled with the findings that Cys90 is highly reactive to
MTS reagents370,371, imply very few surface DATs are acylated at Cys90,
implicating it as an intracellular phenomenon. Because the DHHC domain of the
PAT enzymes lies proximal to the cytoplasmic portion of the membrane 401, the
intriguing palmitoylation/depalmitoylation cycle of Cys90 would occur with the cotranslational attachment of the fatty acid within the ER 373,402; post-translational
Cys90 will be oriented toward the organelle lumen or, while at the PM,
extracellularly, without access to the PAT catalytic motif. The depalmitoylation of
Cys90, therefore, is likewise a lumen event - indicating a PPT-catalyzed process
rather than APT. PPT’s have been classically associated with lysosomal protein
degradation287–289; however, an increasing body of evidence implicates
malfunctioning endosomal290 and synaptic vesicular400,403 PPT1 in infantile
neuronal ceroid lipofuscinosis (INCL) etiology. The presence of this enzyme is
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essential for accurate turnover of several key palmitoylated protein components of
vesicular fusion machinery403 - syntaxin 1a376,377, SNAP25404–407, cysteine string
protein408,409, synaptobrevin410, and synaptotagmin I404,411–413. The significantly
elevated PM population of the Cys90Ala mutant may be an effect of losing
palmitoylation of Cys90 which may sequester the acylated DATs in endosomes;
events which coordinate vesicular DA egress and require activated PPT1 for
recycling of vesicular machinery may concomitantly draw endosomal DATs to the
PM for reuptake of the released transmitter via depalmitoylation of Cys90. Thus
the Ala90 rDAT would lose endosomal retention and display elevated PM
expression (Figure 10d). It is interesting to note that the lack of loss of surface
transporters upon treatment of rat striatal synaptosomes with 2BP may be an effect
of losing Cys90 acylation, which would replenish plasma membrane DAT
populations that traffic away from the plasma membrane in response to loss of
Cys580 acylation, an event which is known to antagonize DAT degradation344. This
implies palmitoylation at different locations of the same substrate protein (90
versus 580) yield opposite phenotypic results.
DAT-mediated substrate translocation requires transition through many
physical permutations of the transporter in an alternating access fashion159,160;
synaptic DA, two Na+172 ions and one Cl-173 ion cosubstrates bind to an outwardopen conformation triggering conformational progression through an occluded
structure and ultimately achieving an inward-open state whereupon substrate and
cosubstrates are released into the cytoplasm157. The substrate permeation
pathway of DAT involves amino acid residues from TMs 1, 3, 6, and 8155. The
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analysis of the DA uptake saturation kinetics revealed Cys90Ala rDATs have
significantly increased Km for DA uptake than their WT counterparts (Figure 14).
From the immediately preceding account of how palmitoylation of Cys90 may
come about, it is unlikely the loss of Ala90’s apparent DA affinity is due to loss of
lipidation of this residue, but rather loss of the chemical interactions supported by
the sulfhydryl side chain with polar head regions of the exofacial leaflet of the PM.
This may produce an instability in TM1, which moves significantly during the DA
transport process, precipitating overall reduction of the integrity of this portion of
the substrate translocation route, hampering these DAT’s ability to interact with
DA. Additionally, a cholesterol molecule binds in a groove formed by TMs 1, 5, and
7155, and an alanine at rDAT position 90 may alter conformational dynamics of this
region. Cholesterol has been demonstrated to be an important influencer of DAT
conformation156 and, therefore, function, stabilizing both forward and reverse DA
transport187. Thus disruption of Cys90 producing a loss of cholesterol-DAT
interaction could also explain the loss of apparent affinity for DA presented by the
Ala90 DATs (Figure 15).
The report on Cys580Ala uptake saturation kinetics yielded surprising
results (Figure 13). Though these experiments, like the previous study of
Cys580Ala rDAT347, were performed in LLCPK1 cells, these DATs were generated
by transient transfection while the former were stably produced. Here the Km was
significantly higher than WT, and Vmax, though apparently elevated, was not
significantly higher. The past report found these transporters have an unchanged
Km for DA but a significantly reduced maximal DA transport velocity347. This may
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be due to altered modification and binding partner interactions of the transiently
versus stably translated proteins or the transfection reagent affecting plasma
membrane characteristics, with trickle-down effect on plasma membrane protein
(DAT) function. Further studies need to be done to determine whether stable or
transient transfection better reflects the in vivo biological reality.
The experiments reporting the 2BP effect on palmitoylation-deficient DATs’
DA uptake capabilities attempt to expand upon previous results demonstrating that
2BP treatment downregulates [3H]DA uptake in rat striatal synaptosome
preparations344, and differentiate between the effects of global and DAT-specific
palmitoylation events on DA uptake (Figure 15). 2BP stimulated loss of DA
reuptake was positively correlated to the number of acylation sites present on the
DATs (Figure 16); The WT transporter population succumbed to the greatest 2BP
generated DA transport loss while the combination Cys6/580Ala transporters were
affected the least. This result stands to reason as a reduction in the number of
DAT acylation sites would indicate the residual loss of function (or gain in the case
of other proteins414) induced by 2BP to be a result of more global palmitoylation
inhibition

than

DAT-subjective

palmitoylation

blockade.

It

is,

therefore,

unsurprising that the Cys6/580Ala rDATs display the least 2BP created loss of
function. Additionally, it should be noted that the mutation of these sites may
produce a priori effects which would otherwise be accounted for by 2BP treatment;
i.e., DAT-interacting proteins may lose their binding interaction due to mutagenesis
of the Cys residue(s) rather than a binding partner losing its palmitoylation moiety
via 2BP rendering it incapable of interacting with DAT. The presence of both Cys6
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and Cys580 may be vital to establish some binding partner interactions; though,
mutagenesis-induced loss of these would-be-interactions produce no change in
uptake kinetics of the Cys6/580Ala rDATs (Figure 13). The Cys90Ala and
Cys6/90/580Ala transporters need to be assessed by this method as it would be
interesting to see if the triple combination DAT-palmitoylation deficient mutant
displays no DA transport loss upon 2BP treatment.
The efflux experiments (Figures 17 and 18) reveal that S-acylation
significantly contributes to DAT-mediated reverse DA transport process. The
hitherto discovered DAT structural and functional factors which support AMPHstimulated DA release are: the NH2-terminus in general362; the specific
phosphorylation thereof228; its PIP2-mediated tethering to the PM232; the induction
of a channel-like mode of the transporter, enabling quantum-like transmitter
release233; ion conductance promulgating PM depolarization 234 producing Ca2+
influx235,236 and propagation of neuronal excitability415; elevated accumulation of
intracellular Na+ ions requisite for DA efflux237; and AMPH action at the cognate
vesicular transporter239,240. The mutation of Cys6 blunted both basal and AMPH
stimulated efflux while Cys580 alteration potentiated AMPH’s DA releasing action
(Figure 17a). This Cys6Ala phenotype may be due to losing PIP2-mediated DAT
N-terminal-PM interplay whose structural outcomes and concomitant protein
interactor differences confer dampened DA efflux characteristics to the transporter.
Ala580 rDAT’s increased capacity for AMPH stimulated release may be due to its
susceptibility toward inherent elevated phosphorylation and is therefore more
prone to AMPH effects. Likewise, palmitoylation of Cys580 stabilizes DA
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reuptake347 and losing this modification may allow easier conformational
isomerization of the transporter and greater substrate access to its inward-open
form, easing substrate efflux. The contrary efflux patterns of Cys6Ala and
Cys580Ala rDATs cancel out in the Cys6/580Ala transporters which behave like
WT DATs upon AMPH treatment, and in like manner Cys90Ala does not deviate
from the AMPH-WT phenotype.
General cellular palmitoylation was demonstrated to contribute significantly
to the DAT-mediated efflux paradigm (Figure 18). WT transporters display 2BPbasal release like AMPH-stimulated release, and 2BP and AMPH induce additive
DA release effects on WT DATs. This is partially due to the ability of 2BP to induce
transporter phosphorylation347, but also loss of lipidation of other proteins which
would propitiate DA efflux parameters: The Na+/K+-ATPase requires palmitoylation
for its function321 and loss thereof would induce efflux-favorable cytoplasmic
accumulation of Na+ ions; DAT-interacting D2 receptors undergo S-acylation136,416
and loss of its palmitoylation may alter its interaction with the transporter, altering
the nature of AMPH-stimulated DA release; 2BP-reduced syntaxin 1a acylation
may support its interaction with DAT, especially if, like DAT, these modifications
interact reciprocally at syntaxin 1a, as the SNARE protein’s enhanced
phosphorylation has been demonstrated to increase its DAT partnering and
promotion of reverse DA transport417. The 2BP treatment of Cys6Ala and
Cys580Ala (Figures 18b and c) transporters generated results congruent with the
AMPH treatment of these transporters alone (Figures 17a and b). Cys6Ala DATs
have potentiated AMPH-induced DA release after incubation with 2BP (Figure
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18b), consistent with losing acylation events at Cys580, and Cys580Ala DATs
display unaltered AMPH-stimulated DA release patterns (Figure 18c), consistent
with losing Cys6 acylation events as the Cys6Ala mutation attenuated DA efflux
(Figure 17a). 2BP had no effect on the induction of either basal or AMPH-propelled
efflux from Cys6/580Ala DATs (Figure 18d). As with the 2BP effect on DA uptake
of these transporters (Figure 15d), this may be due to the structural or interactor
characteristics which would otherwise be altered by 2BP.
This study relates the potential for two additional rDAT S-palmitoylated
residues, Cys6 and Cys90, and the impact these residues have on both forward
and reverse DA transport; Cys6 acylation significantly affects the dynamic of the
NH2-domain and supports DA efflux, and Cys90 acylation has significant
implications for the trafficking of the transporter and the residue is important to the
integrity of the substrate permeation pathway. Importantly, this study implicates
palmitoylation in playing an important role in the complex DA efflux process. Our
lab has demonstrated the hyper effluxing hDAT coding variant Ala559Val 380 to be
deficient in S-palmitoylation, and it is conceivable, in light of this study, that
improper palmitoylation of DAT may contribute to this aberrant efflux phenotype. It
may be possible, therefore, to achieve reversal of this anomalous DA efflux
characteristic via therapeutic intervention at the level of DAT palmitoylation. The
theory of targeting protein palmitoylation to alleviate disease states is not new418,
and with the emergence of multiple illnesses being associated with aberrant
protein S-palmitoylation332,419, psychiatric disorders involving DA homeostasis may
be beneficially impacted through modulation of DAT S-acylation.
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Methods
Cell Culture and Site Directed Mutagenesis
Lilly Laboratory Cell Porcine Kidney (LLCPK1)420 parental cells or LLCPK1
cells stably expressing WT or mutant rDATs were grown in Dulbecco’s Modified
Eagle Medium (DMEM) containing 5% fetal bovine serum, 100 µg/mL
penicillin/streptomycin, and supplemented with 400 µg/mL of the selection reagent
Geneticin (G418) for stably expressing cell lines. Cells were maintained in a
humidified incubator with 5% CO2 at 37oC. Cys to Ala rDAT mutant DNA constructs
were generated using the Stratagene QuickChange® PCR kit from template WT
rDAT pcDNA 3.0 vector cDNA, and nucleic acid substitution was confirmed by
sequencing (Eurofins MWG). For generation of multiple Cys to Ala substitutions,
sequential addition of mutations were performed such that Cys135Ala mutation
was introduced into the Cys6Ala rDAT template and subsequently Cys341Ala
mutation was introduced into the Cys6/135Ala rDAT template until all the rDAT
cDNA constructs containing only one intracellular Cys residue were produced.
Transfection
For generation of cell lines stably expressing WT or mutant rDAT
constructs421, LLCPK1 parental cells were seeded into 12-well plates and grown to
~50% confluence. At this point the cells were transfected. X-tremGENE
transfection reagent was mixed with plasmid DNA (1.4 µg of DNA/well) at a
reagent:DNA ratio of 3:2 in OptiMEM for 20 min at ambient temperature after which
the transfection complex was added to each well dropwise. After ~36 hours, the
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cells were then transferred to a culture flask to undergo selection of expressing
cells via 800 µg/mL G418 treatment. After two subculture passages at this G418
concentration, the cells were collected, the plasma membranes were harvested,
and expression of rDAT was analyzed by immunoblotting with the anti-DAT mouse
monoclonal antibody MAb16. If the transfection was successful, the stably
expressing rDAT cells were maintained in 400 µg/mL of G418 for all subsequent
uses. For transient production of the desired rDATs, LLCPK1 parent cells were
seeded into 24-well (0.5 µg DNA/well) or 100 mM plates (5 µg DNA/plate) and
grown to ~80% confluence. X-tremeGENE transfection reagent was mixed with
plasmid DNA at an X-tremeGENE:DNA ratio of 3:2 in OptiMEM for 20 min at
ambient temperature. After the incubation, the transfection construct was added to
each well containing 0.5 mL of DMEM for 24-well plates or 5 mL of DMEM for 100
mM plates. Experiments were performed ~36 hours post-transfection.
SDS-PAGE and Western Blotting
DAT proteins and peptides were denatured in Laemmli sample buffer (SB:
125 mM Tris-HCl, 20% glycerol, 4% SDS, 200 mM DTT, 0.005% bromophenol
blue) and were electrophoretically resolved using 4-20% polyacrylamide gels
alongside a ColorBurst protein standard. Proteins were then transferred to a
transfer buffer (25 mM Tris-HCl, 192 mM Glycine, 0.1% SDS, 10% methanol) equilibrated polyvinylidene fluoride (PVDF) membrane after which blocking was
performed with a 3% BSA/PBS buffer. Primary MAb16 antibody was diluted
1:1,000 in the blocking solution and the blocked PVDF membrane was incubated
in this antibody solution for 1 hour at ambient temperature. After five washes the
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membrane was incubated in alkaline phosphatase (AP)-linked anti-mouse IgG
secondary antibody diluted to a 1:5,000 ratio in blocking buffer for 1 hour followed
by 5 additional washes. 3 mL of Immun-Star™ AP substrate (Bio-Rad) was applied
to the membrane and incubation proceeded for 5 min at ambient temperature.
Generated chemiluminescent Western blot band intensities were quantified using
Quantity One® software (Bio-Rad).
Plasma Membrane Preparation
rDAT-LLCPK1 cells expressing the indicated DATs were grown in 150 mm
plates to ~90% confluency. Cells were washed twice with Buffer B (0.25mM
sucrose, 10 mM triethanolamine, and pH was adjusted to 7.8 with 100 mM acetic
acid), scraped, and collected in Buffer B containing a protease inhibitor cocktail of
1 µM phenylmethylsulfonyl fluoride (PMSF) and 5 µM Ethylenediaminetetraacetic
acid (EDTA) at 4oC. Cells were then pelleted via centrifugation at 3,000 x g for 5
min at 4oC, supernatants were removed, and the cell pellets were suspended in
Buffer C (0.25 M sucrose, 10 mM triethanolamine, 1 mM EDTA, and the pH was
adjusted to 7.8 with 100 mM acetic acid) and subsequently homogenized using 30
up and down strokes in a Dounce homogenizer. Cellular debris and nuclei were
cleared from the homogenates by centrifugation at 800 x g for 10 min. The postnuclear supernatant was collected and centrifuged at 18,000 x g for 12 min, and
the resulting plasma membrane pellet was suspended in sucrose phosphate (SP)
buffer (10 mM sodium phosphate, 0.32 M sucrose, pH 7.4 with 1 µM PMSF and 5
µM EDTA).
Synaptosome Preparation
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Male Sprague-Dawley rats weighing between 200 and 300g were
decapitated, and striatal hemispheres were excised, weighed, and stored in icecold SP buffer. The striata were homogenized in 2 mL ice-cold SP buffer with 30
up and down strokes in a glass-Teflon homogenizer, diluted with a further 8 mL
SP buffer, and centrifuged at 3000 x g for 2 min at 4oC. The supernatant fraction
was isolated and subjected to an additional centrifugation at 15,000 x g for 12 min.
The resulting P2 pellet encompassing synaptosomes was suspended in SP buffer
with protease inhibitors and the tissue was diluted to 20 mg/mL using the original
wet weight of the striatal tissue.
Asp-N Endoproteinase Proteolysis
Striatal synaptosomes or membranes from rDAT expressing LLCPK1 cell
were prepared as described above and divided equally into two microfuge tubes.
The preparations were acetone precipitated with an acetone to sample volume
ratio of 4:1 for 1 hour at -20oC. The pellets were suspended in SP buffer and equal
volumes were divided between one control and one Asp-N treated microfuge tube.
The same volume of SP was added to the negative control test tube and SP buffer
containing 2 μg/mL endoproteinase Asp-N was added to the treatment test tube
creating a final endoproteinase concentration of 1 μg/mL. For membrane
preparations, 0.1% SDS (v/v) was added to the digestion and control samples.
Enzymatic digestions were carried out for 45 minutes at ambient temperature with
nutation. Both samples were then centrifuged at 18,000 x g for 12 min at and the
resultant pellet was used for further experimentation.
CNBr Chemical Proteolysis
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Equal volumes of striatal synaptosomes or membrane preparations of the
indicated rDAT-expressing LLCPK1 cells were divided into CNBr treated or control
microfuge tubes and acetone precipitated with 4x sample volume for 1 hour at 20oC. The samples were centrifuged at 18,000xg for 10 minutes and supernatants
were removed. Precipitated experimental pellets were then suspended in 70 µL
formic acid, 10 µL water, and 20 µL 5M CNBr (1M final concentration) or 70 µL
formic acid and 30 uL water for untreated samples. Digestion was performed for
1 hour at 25oC in the dark. CNBr was removed via 3 repetitions of dilution with
900uL water and lyophilization. Final pellets were then used in subsequent
experimentation.
Acyl-Biotinyl Exchange
Our ABE method was adapted from Wan et al341 where detection of
palmitoylated proteins are described in three steps: Free cysteine thiols are
blocked; thioester linked palmitoyl groups are specifically removed by
hydroxylamine (NH2OH); and the previously palmitoylated and now free sulfhydryl
groups are biotinylated. Membranes isolated from WT rDAT or rDAT mutant
LLCPK1 cells or rat striatal synaptosome preparations were solubilized in 250 µL
of ABE lysis buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing
protease inhibitor and 20mM methyl methanethiosulfonate (MMTS) to react with
unbound Cys sulfhydryl moieties and incubated for one hour at ambient
temperature. MMTS was removed by a 1 mL acetone precipitation and
centrifugation at 18,000 x g for 10 min. The pellet was dissolved in 250 µL 4SB
ABE buffer (50 mM Tris, 5 mM EDTA, 4% SDS, pH 7.4) and remnant MMTS was
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removed by an additional 1 mL acetone precipitation and centrifugation. The pellet
was then subjected to a further acetone wash. The pellet was suspended in 200
µL 4SB buffer and thioesterified palmitate molecules were specifically removed by
hydroxylamine (NH2OH); The sample was split equally (100 µL) into negative
control (800 µL, 50 mM Tris-treated) and NH2OH -treated (1.4 mM) halves and
incubated at ambient temperature for 30 min with end-over-end mixing. The free
sulfhydryl groups were reacted with 100 µL (0.4 mM final concentration) of a
sulfhydryl-specific biotinylating reagent, HPDP-biotin in the Tris or NH2OH
mixtures. The now HPDP-biotin-containing samples were incubated for 3 min in a
37oC water bath then at ambient temperature for 1 hour. Excess NH2OH and biotin
reagents were removed by the 4:1 acetone to sample volume precipitation,
centrifugation at 18,000 x g, supernatant aspiration, 250 µL 4SB pellet suspension,
1 mL acetone precipitation, centrifugation at 18,000 x g, supernatant aspiration, 1
mL acetone wash, centrifugation at 18,000 x g, and supernatant aspiration
workflow. The final pellet was suspended in 75 µL ABE lysis buffer and 10 µL of
this was set aside for total DAT immunoblotting while 65 µL was added to 50 µL of
a 50% slurry of Neutravidin resin in 1500 µL Tris buffer to affinity purify the
biotinylated proteins or peptides overnight at 4oC with nutation. Unbound peptides
were washed away by three cycles of 8,000 x g centrifugation and 900 µL radio
immunoprecipitation assay buffer (RIPA: 1% Tx-100, 1% sodium deoxycholate,
0.1% SDS, 125 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM NaF).
Proteins and peptides were eluted from the final pellet by incubation in 2x Laemmli
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SB for 20 min at ambient temperature. Samples were then subjected to SDSPAGE, and immunoblotted with mouse anti-rDAT primary antibody (MAb16).
2BP DA Uptake Assay
LLCPK1 parent cells were grown in 24-well plates until ~80% confluent then
were transiently transfected with the indicated rDAT DNA. 36 hours prior to the
assay, the cells were washed with 0.5 mL 37oC KRH buffer and resupplied with
KRH buffer with or without 7.5 µM 2BP for 90 min at 37 oC and 5% CO2. After the
2BP incubation, DA uptake was conducted for 30 min at 37oC with 3 µM total DA
containing 10 nM [3H]DA. Excess DA was rapidly washed out with KRH buffer and
the cells were lysed with 1% Tx-100 for 20 min at ambient temperature. Lysates
were collected and analyzed for [3H] content by liquid scintillation counting. 2BP
uptake data are presented as % uptake control.
DA Efflux Assay
LLCPK1 parent cells were seeded onto 24-well assay plates at 50,000
cells/well and allowed to grow to ~80% confluence (~24 h). Cellular production of
WT or mutant DATs was induced by transient transfection for ~36 hours prior to
assay. DAT-expressing LLCPK1 cells were loaded via DA DAT-mediated uptake
of 3 µM DA containing 10 nM [3H]DA for 30 minutes in 37oC Krebs Ringer/HEPES
buffer (KRH, 25 mM HEPES, 125 mM NaCl, 2.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 5.6 mM glucose, 1.3 mM CaCl2, 1.1 mM ascorbic acid). Extracellular DA
was washed out 3 times with 4oC KRH on ice, and the assay plate was transferred
back to the water bath and 37oC KRH efflux buffer with or without 10 µM AMPH
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was rapidly added to avoid cell drying and displacement upon buffer addition. The
efflux buffer was collected after one minute and analyzed for radioactive content;
one column of cells received no efflux buffer and was lysed with 1% Triton X-100
for 20 min at ambient temperature and served as the total internal [ 3H]DA control
and was analyzed in parallel for [3H] content by liquid scintillation counting. The
efflux values are expressed as a percent of the total intracellular [3H]DA. Where
indicated cells were incubated with 7.5 µM 2BP in KRH for 90 min prior to the 30
min load portion of the experiment.
DA Uptake Saturation Analysis
Saturation analyses were performed on LLCPK1 cells transiently producing
WT or mutant DATs in 24-well assay plates 36 h post-transfection. The cells were
rinsed once and then resupplied with 0.5 ml of 37oC KRH buffer. The DA
concentrations used were varied from 0.32 µM to 20 µM containing 10 nM [3H]DA
and uptake was performed in triplicate for 8 min; nonspecific uptake was
determined by DA uptake in the presence of 100 µM (-)-cocaine. After 8 min, cells
were rapidly washed 2 times with ice-cold KRH buffer and solubilized in 1% Tx100 for 20 min at ambient temperature with rocking. Radioactive DA present in the
collected lysates was assessed by liquid scintillation counting. Kinetic values were
analyzed using Prism software, and Vmax values for each DAT line were normalized
to transporter surface levels determined by surface biotinylation assays performed
in parallel for each experiment.
Surface Biotinylation
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LLCPK1 parent cells were seeded onto 24-well assay plates and grown to
~80% confluence at which point 12 wells of each plate were transiently transfected
with the indicated rDAT plasmid 36 hours prior to the biotinylation assay. After
transfection the cells were washed three times with ice cold Hank’s balanced salt
solution containing Mg+ and Ca2+ ions (HBSS Mg-Ca: 1mM MgSO4, 0.1 mM CaCl2,
pH 7.4), and subsequently incubated twice with 0.5 mg/mL of membraneimpermeable sulfo-NHS-SS-biotin for 25 min on ice with rocking. The biotinylation
reagent was removed and the reaction was quenched by two sequential
incubations with 100 mM glycine in HBSS Mg-Ca for 20 min on ice with rocking.
Cells were washed with HBSS Mg-Ca and lysed with 125 µL RIPA buffer
containing protease inhibitor in each well after which the lysates from 12 wells (one
full DAT line) were collected in a 2 mL microcentrifuge tube. 100 µg of protein from
each lysate were incubated with NeutrAvidin beads overnight at 4°C with nutation.
The beads were washed three times with RIPA buffer and the bound protein was
eluted with 32 µl of SB followed by SDS-PAGE and immunoblotting for DAT with
MAb16.
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CHAPTER 3
EFFECTS OF THE PARKINSON-INDUCING NEUROTOXINS MPP+ AND 6OHDA ON DOPAMINE TRANSPORTER FUNCTION AND MODIFICATION
Abstract
Synaptic action of the neurotransmitter dopamine (DA) is primarily
terminated by reuptake into presynaptic dopaminergic neurons via dopamine
transporters (DATs). DATs are integral plasmalemmal proteins whose reuptake
function is tightly coordinated by interplay between the post translational
modifications

phosphorylation

and

palmitoylation.

The

psychostimulant

amphetamine (AMPH) is a DAT substrate known to empty sequestered DA from
vesicles and induce protein kinase C (PKC)-dependent DAT phosphorylation,
resulting in reverse transport of DA (efflux) and greatly increased DA signaling.
Elevated DA concentrations similar to those produced by AMPH create neurotoxic
conditions as DA oxidation produces free radicals and hinders mitochondrial
respiration, thus strict spatial and temporal control of cytosolic and synaptic DA is
essential for neuronal health. DA induced oxidative stress is an important
pathogenic mediator in Parkinson disease (PD), and animal models of PD are
generated by the neurotoxins 1-methyl-4-phenylpyridinium ion (MPP+) and 6hydroxydopamine (6-OHDA) which selectively target DAT-expressing neurons,
are translocated to the cytosol by DAT, and perturb the oxidative balance within
the cell to produce the nigrostriatal DA neuron death observed in PD. It is therefore
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intriguing to investigate DAT-involved mechanisms in terms of PD etiology as
atypical DAT function could contribute to DA oxidative stress and is hypothesized
to play a role in other neurological disorders including attention deficit/hyperactivity
disorder (ADHD) and addiction. DAT expression occurs around synaptic terminals,
along axons, and on dendritic spines, and efflux via DATs located on dendrites in
the substantia nigra has been shown to diminish dopaminergic signaling. It is
possible, therefore, for aberrant regulation and localization of DA clearance and
DAT-mediated DA efflux to profoundly influence the excitability of neurons and play
a significant role in neurodegeneration in the progression of PD. This is even more
interesting in the light of recent studies revealing DAT polymorphisms in patients
diagnosed with a psychiatric disorder or early onset PD that display an elevated
basal DA efflux phenotype. In this study, we are investigating the effect of DAT
substrates and PD-inducing neurotoxins on DAT phosphorylation, palmitoylation,
down-regulation, and reverse transport to better understand aberrant DAT
mechanisms which may contribute the onset of PD. Our findings indicate MPP+
and 6-OHDA differentially alter DAT function. 6-OHDA inhibits basal and
attenuates PMA-induced DAT phosphorylation, does not significantly reduce DA
uptake, and decreases DA efflux. MPP+ does not change basal or PMA stimulated
DAT phosphorylation yet it induces significant DA efflux which may be an
additional means by which MPP+ produces neurodegeneration. This MPP+ induced
efflux

was

not

abolished

by

pretreatment

with

the

PKC

inhibitor

bisindolylmaleimide (BIM). Although AMPH-induced efflux was blunted after BIM
treatment, significant efflux remained, supporting evidence of mechanisms
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independent of PKC mediated DAT phosphorylation for the stimulation of DA
efflux.
Introduction
Parkinson Disease (PD) is the second most common neurodegenerative
illness and its prevalence is expected to increase proportionately with the size of
aging populations422. PD pathology423 is characterized by progressive, selective424
loss of substantia nigra (SN) pars compacta dopamine (DA) neurons and
aggregation of proteinaceous fibril superstructures, comprised primarily of αsynuclein, known as Lewy bodies425. The clinical presentation of this illness,
though phenotypically heterogeneous, is manifest through aberrant locomotor
output in the form of bradykinesia, resting tremor, postural instability, and/or
rigidity426; however, onset of these symptomatic traits generally does not appear
until 66%-80%352 of SN DAergic neurons are lost, generating further striatal DA
deficiency427 and causing the resultant motor dissonance to occur. These data
spurred interest in finding prodromal manifestations of PD, and associations
between disease onset and manifold pre-motor symptoms were established428,429:
olfactory malfunction430; rapid eye movement sleep behavior disorder431,432;
constipation433,434; and depression435,436 with antidepressant use have been
identified as potential pre-motor symptoms in PD development. PD treatment
methodologies437 target motor symptoms of the disorder and primarily entail
replenishing DA function via increasing striatal DA concentration through elevating
DA synthesis with the product of its rate-limiting enzymatic step, levodopa,
mimicking synaptic DA action by DA receptor agonists, or attenuating enzymatic
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DA degradation with monoamine oxidase and/or catechol-o-methyl transferase
inhibitors438. While these pharmacotherapies improve quality of life, their long-term
use, coupled with the progression of the disease, result in increasing severity of
symptoms including dementia, dyskinesia, and psychosis439,440.
At a biochemical level, PD etiology has been linked to several protein
and organellar malfunctions. Inherited PD stems from polymorphisms of genes
coding for α-synuclein, E3 ubiquitin ligase, leucine-rich repeat kinase 2, and other
proteins253,441, while idiopathic PD derives from numerous risk factors like
exposure to pesticides and use of beta blockers442. The resultant synuclein
aggregation induces cellular damage through endoplasmic reticulum stress,
mitochondrial impairment443, neuroinflammation444, and reactive oxygen species
production445, all of which induce cell death. As previously mentioned, the locus
and cell type of these apoptotic events is a common link between inherited and
idiopathic PD and that is consistent loss of substantia nigra DA neurons. A
peculiarity of this subset of neurons is their high expression of the DA transporter
(DAT), the high-affinity DA reuptake protein139,446. Indeed, the extent of PDinduced loss of DAergic neurons from the brain’s primary DA pathways is greatest
in the nigrostriatal tract352, followed by ventral tegmental area-originating
mesocoritcal and mesolimbic structures447,448, while the tuberoinfundibular tract
remains largely unaffected424. These losses positively correlate with both DAT
mRNA449–451 and protein expression452,453 in these regions. It is for this reason DAT
has been hypothesized as a molecular gateway through which PD pathogenicity
occurs251,454.
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Two neurotoxic compounds used extensively in laboratories to create
facsimiles of PD for study in multiple model systems operate as DAT substrates;
their experimental efficacy is due to their transport selectivity by DAT and therefore
poison

neurons

specifically

expressing

DATs.

These

compounds,

6-

hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) (Figures 1 & 2), induce the DAergic neuron losses characteristic of PD,
and do so through overlapping biochemical mechanisms455. Under physiologic
conditions 6-OHDA induces cell death after rapid auto-oxidation456 and generation
of oxygen-derived free radical species457,458, perhaps through iron-catalyzed ROS
activity459,460. Additionally, 6-OHDA inhibits complex I of the mitochondrial electron
transport chain461,462 and induces neuronal death primarily through apoptotic
pathways463. MPTP neurotoxicity occurs after its monoamine oxidase conversion
to 1-methyl-4-phenylpyridinium (MPP+) in astrocytes464,465, flux from these cells
through organic cation transporter 3466 or extraneuronal monoamine transporter467,
and neuronal entry via DAT. Once in the cytosol, MPP+ is sequestered into vesicles
through VMAT2468,469 which empties vesicular DA into the cytosol, producing its
oxidation by-products and their concomitant oxidative damage470,471. MPP+
likewise inhibits mitochondrial ATP production443,472, but unlike 6-OHDA, has been
shown to destabilize cytoskeletal structures473,474, and cause acute increased
striatal DA release475,476. The toxic functional outcomes of these compounds are
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Figure 1. Chemical structures of 6-OHDA and MPP+. Chemical structures of
Dopamine
(top),
6-hydroxydopamine
(middle),
and
1-methyl-4phenylpyridinium (bottom).
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Figure 2. Known neurotoxic mechanisms of 6-OHDA and MPP+. Schematic
diagram of DA, 6-OHDA, and MPP+ Neurotoxic mechanisms. After synthesis,
DA is packaged into vesicles via the vesicular monoamine transporter where it
is trafficked to the plasma membrane for exocytotic release into the synapse.
Cytosolic DA metabolism is known to generate ROS. DA can be oxidized to
form reactive quinones that react further on to form neurotoxic compounds and
protein adducts. MPP+ is enzymatically generated in glial cells via MAO. 6OHDA and MPP+ enter neurons through DAT and induce their toxic effects by
inhibition of complex I of oxidative phosphorylation, formation of ROS by lipid
peroxidation, or disruption of cytoskeletal integrity.
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dependent upon their DAT-mediated entry into neurons477–479, and many of their
DAT-specific effects have hitherto been unexplored.
This study investigates the biochemical effects exerted by the PDgenerating neurotoxins upon heterologously expressed DATs; DA reuptake, DA
reverse transport, DAT phosphorylation, and DAT palmitoylation changes induced
by 6-OHDA and MPP+ were assessed. Our findings reveal that, despite sharing
multiple cytotoxic mechanisms, 6-OHDA and MPP+ have striking dissimilarities in
regards to DAT phosphorylation, DA uptake downregulation, and DAT-mediated
DA efflux. Significantly, this study further investigates the DA efflux phenomenon
associated with early onset PD and ADHD, an event recapitulated by MPP +, and
highlights the extreme caution needed in prescribing or using pharmaceuticals
inducing carrier-mediated DA efflux.
Results
6-OHDA and MPP+ Competitively Inhibit DAT-mediated DA Uptake
To investigate the concentrations at which DA uptake by WT rDATs in
LLCPK1 expression systems were inhibited by 6-OHDA and MPP+, competition
uptake assays were utilized. The half maximal inhibitory concentration (IC 50) was
determined for the LLCPK1 – WT rDAT model by [3H]DA uptake assays with
unchanged 0.5 µM DA in the presence of increasing concentrations (10 -7 to 10-1
M) of 6-OHDA or MPP+ (Figure 3). The IC50 for 6-OHDA was approximately 1mM
(1025 ± 185 uM, n=2 independent experiments performed in triplicate), and the
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Figure 3. MPP+ has a 16-fold greater potency than 6-OHDA for the inhibition
of DA uptake. LLCPK1-rDAT cells were assayed for [3H]DA uptake activity in
the presence of 10-7- 10-1 M 6-OHDA or MPP+. Reactions contained 0.5 µM DA
with the indicated inhibitor concentration and were conducted at 37°C for 8 min
after which cells were washed, lysed, collected, and analyzed for radioactivity by
scintillation counting. IC50 values for 6-OHDA and MPP+ were determined by
non-linear regression analysis and data are presented as mean ± S.E. of two
experiments carried out in triplicate. Foster and Vaughan, unpublished data.
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MPP+ IC50 was 64.4 ± 10.3 µM (n=2 independent experiments performed in
triplicate). While these compounds do not have particularly high affinity for the DA
translocation site on DAT (for reference, see DA saturation analysis studies in
chapter II), they do exhibit competitive inhibition of DA uptake, indicating
competition for the primary substrate permeation pathway of DAT in LLCPK1 cells.
This, of course, corresponds with what has been known about these compounds
for some time – they require DAT to enter DAergic neurons to exert their neurotoxic
effects. Also, as DA uptake was competitively inhibited by 6-OHDA and MPP+,
these experiments indicate the LLCPK1 – DAT model system is valid to utilize for
further experimentation with these compounds.
6-OHDA and MPP+ Induce Downregulation of DAT Activity
The extent to which the neurotoxic DAT substrates are able to downregulate
DAT uptake capacity was next interrogated. 20 µM of 6-OHDA, MPP+, and DA in
parallel with 400 nM phorbol-12-myristate-13-acetate (PMA), a PKC-activator
known to down-regulate DAT function yet not requiring DAT activity to enter the
cell’s cytoplasm, were applied to LLCPK1 cells expressing WT rDAT 30 minutes
prior to washout with 4oC KRH and [3H]DA uptake testing (Figure 4). In these
experiments, MPP+ (p<0.01 versus 6-OHDA) and DA (p<0.05 versus 6-OHDA)
induced significantly greater downregulation of DAT function than did 6-OHDA,
though no substrate attenuated DAT activity to the extent of PMA. These results
indicate these DAT substrates produce down regulatory effects on DAT-mediated
DA uptake, but do so, perhaps, by varying means. That 6-OHDA induces
significantly less uptake attenuation may indicate it affects DAT internalization or
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Figure 4. 6-OHDA induces DAT downregulation to a significantly lesser
extent than DA or MPP+. LLCPK1-rDAT cells were pretreated with vehicle, 400
nM PMA, 20 µM DA, 20 µM 6-OHDA, or 20 µM MPP+ at 37°C for 30 min
followed by rapid washout at 4°C prior to assay for DA uptake. Down-regulation
is reported as the percent difference in transport activity between the vehicle
and substrate or PMA pretreatments. Data are presented as mean ± S.E. of
two experiments carried out in triplicate. **p<0.01 MPP+ versus 6-OHDA,
*p<0.05 DA versus 6-OHDA. Foster and Vaughan, unpublished data.
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regulatory pathways differently than MPP+ or DAT’s cognate substrate, DA; though
MPP+ induced effects similar to DA on DAT activity, this by no means indicates
they operate through similar mechanisms to blunt DAT function.
Incubation of 6-OHDA and MPP+ on DAT-Expressing Cells Affects DA
Uptake and Requires Functional DATs
To delineate whether the functional downregulation generated from the
activity of 6-OHDA and MPP+ results from the active DAT-mediated translocation
of these compounds into the cell or allosteric, extracellular binding events, DA
uptake activity was assessed after incubation of these substances in the absence
or presence of the high affinity DAT inhibitor, cocaine. This was assessed via
incubating LLCPK1 cells expressing WT rDAT with 20 µM of each neurotoxin in
parallel with 20 µM DA and 400 nM PMA for 30 minutes prior to drug washout and
[3H]DA uptake analysis (Figure 5). As a control to demonstrate that any effect 6OHDA or MPP+ produces on DA uptake results from their DAT-mediated entry into
the cell, the indicated incubations were simultaneously performed in the presence
of 100 µM of cocaine. The results of these experiments show incubation with MPP+
(p<0.01), like PMA (p<0.05) but unlike 6-OHDA (p>0.05) significantly reduces
subsequent DAT mediated DA uptake vs. control. The concomitant incubation of
the tested compounds with cocaine successfully blocked the MPP+-induced DA
uptake losses observed in the absence of cocaine (p>0.05). The short incubation
period utilized (30min) hints at acute effects on intrinsic DAT properties such as
conformational alterations, binding partner interactions, post-translational
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Figure 5. Neurotoxin downregulation of DAT requires their DAT-mediated
transport. LLC-PK1-rDAT cells were pretreated with vehicle, 400 nM PMA, 20
µM DA, 20 µM 6-OHDA, or 20 µM MPP+ at 37°C for 30 min with or without 100
µM cocaine followed by rapid washout at 4oC prior to assay for DA uptake with
3 uM DA containing 10 nM [3H]DA for 8 min at 37oC. Cells were rapidly washed
and lysates were collected and analyzed for radioactive DA content by
scintillation counting. Uptake is reported as the percent vehicle control.
**p<0.01 MPP+ versus Control, *p<0.05 PMA versus Control. These results
indicate MPP+ induces significant DAT activity downregulation and requires
DAT-mediated cell entry to achieve this effect.
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modifications, or transporter internalization, rather than the generation of celltoxifying reactive oxygen species, which take more time to be produced and built
up to an extent at which they can induce significant cell damage. These
compounds require DAT-mediated cell entry.
Neurotoxin Effects on DAT-Mediated Reverse DA Transport
Reverse transport (efflux) of DA via DAT has been implicated in the
neuropathology of ADHD and Parkinson’s disease. It follows, then, that an
additional mechanism by which 6-OHDA or MPP+ may be able to induce its
neurotoxic effects is the generation of DAT-mediated DA efflux. To test this we
performed a biochemical efflux assay which involves ‘loading’ DAT-expressing cell
system with [3H]DA through DAT-mediated uptake for 30 min, followed by 3
washouts of extracellular radiolabeled DA with 4oC KRH on ice. Efflux is
subsequently induced by the addition of the 37oC KRH efflux buffer containing
vehicle (to determine the basal efflux level), AMPH (strong DAT-mediated DA
efflux inducer, positive control), or the indicated neurotoxin for 5 minutes. This
buffer is then collected and assayed for radioactivity by scintillation counting.
These efflux experiments were conducted at the sub IC50 concentrations used in
the previous experiments (Figure 6) as well as the determined IC50 values (1 mM
for 6-OHDA and 60 µM for MPP+) (Figure 7) determined from the experiments
described in figure 1. Interestingly, the results of the efflux studies strongly
implicate MPP+ as an efflux inducing compound at both 20 µM (p<0.05 versus
Basal) and its IC50, 60 µM (p<0.01 versus Basal). Additionally, though not
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Figure 6. 20 µM MPP+ induces DA efflux. LLCPK1 cells expressing wild
type rat DAT were grown in 24-well plates and subjected to the DA efflux
assay. Efflux was induced by the addition of 37 o KRH buffer alone to
determine basal efflux or KRH containing 10 µM AMPH, 20 µM 6-OHDA, 20
µM MPP+ to determine compound-induced DA efflux (n=3). The efflux buffer
was collected after 5 minutes and analyzed for radioactivity by scintillation
countining. *p<0.05 MPP+ versus Basal and 6-OHDA, ***p<0.001 MPP+
versus AMPH, ***p<0.001 AMPH versus Basal and 6-OHDA. Data are
presented as % internal [3H]DA. Statistical analyses were performed by
ANOVA with Tukey’s post hoc test of mean ± S.E. These results indicate
MPP+ induces DAT-mediated DA efflux.
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Figure 7. IC50 concentration of neurotoxin effect on DA efflux. LLCPK1
cells expressing wild type rat DAT were grown in 24-well plates and
subjected to the biochemical DA efflux assay. Efflux was induced by the
addition of 37o KRH buffer alone to determine basal efflux or KRH containing
10 µM AMPH, 1 mM 6-OHDA, 60 µM MPP+ to determine drug-induced efflux
(n=3). The efflux buffer was extracted after 5 minutes and assayed for
radioactivity by scintillation counting. **p<0.01 MPP+ versus Basal and
AMPH, ***p<0.001 MPP+ versus 6-OHDA, ***p<0.001 AMPH versus Basal
and 6-OHDA. Statistical analyses were performed by ANOVA with Tukey’s
post hoc test of mean ± S.E. These experiments confirm MPP + is a strong
inducer of DA efflux as the IC50 concentration produced marked increase in
DA efflux.

122

statistically significant, 6-OHDA tended to lower DA efflux in rDAT LLCPK1
systems at both 20 µM (p>0.05 versus Basal) and 1 mM (p>0.05 versus Basal).
This same experiment paradigm was applied to human DAT (hDAT)
expressing LLCPK1 cells to determine whether the same efflux event is produced
by MPP+ interaction with the human DAT isoform (Figure 8). MPP+ did induce
significantly increased levels of DA release relative to basal control from hDAT
LLCPK1 cells (p<0.001 versus Basal). Additionally, 6-OHDA significantly reduced
DA efflux from WT hDAT cells (p<0.01 versus Basal) supporting the trend seen
with WT rDAT cells (Figures 6 & 7). These experiments reveal two distinct
mechanisms by which neurotoxicity may occur: the AMPH-like rapid release and
increase of extracellular DA concentration produced by MPP +, and the blunting of
DAT-mediated DA release seen after 6-OHDA treatment, resulting in elevated
cytosolic DA tone and increased potential for generation of DA oxidation species.
To our knowledge, 6-OHDA attenuation of DA efflux represents the first finding of
a DAT substrate blunting the DA efflux effect.
Inhibiting PKC Reduces Neurotoxin-Induced DA Efflux
An important molecular mechanism involved in DAT-mediated DA efflux is
phosphorylation of the transporter by PKC. To determine if this kinase’s activity
contributes to the elevated DA efflux induced by MPP+ treatment or the reduced
DA release event initiated by 6-OHDA exposure, the previously utilized
biochemical DA efflux assay was conducted after inhibition of PKC with 10 µM of
the PKC inhibitor bisindolemaleimide (BIM) during the 30 minute DA uptake load
phase. 20 µM and IC50 concentrations of each neurotoxin were used on both BIM
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Figure 8. 6-OHDA blunts DA efflux from WT hDATs. LLCPK1 cells
expressing wild type human DAT were grown in 24-well plates and subjected
to the biochemical DA efflux assay. Efflux was induced by the addition of 37o
KRH buffer alone to determine basal efflux or KRH containing 10 µM AMPH, 1
mM 6-OHDA, 60 µM MPP+ to determine drug-induced efflux (n=3). The efflux
buffer was extracted after 5 minutes and assayed for radioactivity by scintillation
counting. ***p<0.001 MPP+ versus 6-OHDA and Basal, **p<0.01 6-OHDA
versus Basal, ***p<0.001 AMPH versus 6-OHDA and Basal. Statistical
analyses were performed by ANOVA with Tukey’s post hoc test of mean ± S.E.
This set of experiments further support MPP+ as an efflux inducer and
demonstrate 6-OHDA as an inhibitor of the DAT-mediated DA efflux process.
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treated and untreated LLCPK1-rDAT cells (Figures 9 & 10). Additionally, BIM
inhibition of PKC was tested in regards to the AMPH-stimulated DA efflux
mechanism as well (Figure 11). Both basal (p<0.01 versus Basal) and 20 µM 6OHDA treatment (p<0.01 versus Basal) saw reduced DA efflux upon BIM
treatment relative to untreated basal release (Figure 9). These data demonstrate
that steady-state PKC activity, and likely phosphorylation of DAT itself, significantly
contributes to a homeostatic DA leak through DAT. The extent of this basal release
is no doubt exacerbated by 30 minutes of DA intake; nonetheless, unstimulated
DAT-mediated DA release activity is significantly lessened by PKC inhibition. That
20 µM 6-OHDA release characteristics were further blunted by BIM treatment is
unsurprising as both molecules likely function through different mechanisms to
modulate DAT-mediated efflux. While at 1 mM, 6-OHDA may interfere with BIMinduced mechanisms other than DAT phosphorylation through PKC, as the 5
minute 6-OHDA exposure is likely insufficient to alter this DAT PTM, yet does
relieve the BIM-induced DA efflux attenuation. Once again MPP+ induced
significantly elevated DA efflux (Figure 10) at both 20 (p<0.05 versus Basal) and
60 µM (p<0.001 versus Basal) concentrations relative to basal control values and
the 60 µM event was reduced upon PKC inhibition (p<0.001 versus MPP+ 60 µM).
BIM treatment preceding 20 µM MPP+-stimulated efflux did not significantly reduce
the release pattern relative to the untreated 20 µM MPP+ paradigm (p>0.05 versus
Basal) though this same BIM exposure did not eliminate the significant increase
relative to the basal control release (p>0.05 20 µM MPP+ + BIM versus Basal). And
though BIM treatment did not completely ablate 60 µM MPP+ activation of efflux
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Figure 9. PKC inhibition effect on 6-OHDA DA efflux signature. LLCPK1
cells expressing wild type rat DAT were grown in 24-well plates and subjected
to the DA efflux assay after BIM treatment. Efflux was induced by the addition
of 37o KRH buffer alone to determine basal or KRH containing 20 µM or 1 mM
6-OHDA (n=3) and collected 5 minutes subsequently and assessed for
radioactivity by scintillation counting. Data are presented as % internal [3H]DA.
100% internal [3H]DA was determined by lysing and assessing radioactive
content of cells receiving no efflux buffer. **p<0.01 Basal versus Basal + BIM
and 6-OHDA 20 µM + BIM, *p<0.05 6-OHDA 1 mM versus Basal + BIM and 6OHDA 20 µM + BIM. Statistical analyses were performed by ANOVA with
Tukey’s post hoc test of mean ± S.E.
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Figure 10. PKC inhibition reduces MPP+-induced DA efflux. LLCPK1 cells
expressing wild type rat DAT were grown in 24-well plates and subjected to the
biochemical DA efflux protocol after BIM treatment. Efflux was induced by the
addition of 37o KRH buffer alone to determine basal or KRH containing 20 µM
or 60 µM MPP+ (n=3) and collected 5 min subsequently and assessed for
radioactivity by scintillation counting. Data are presented as % internal [3H]DA.
100% internal [3H]DA was determined by lysing and assessing radioactive
content of cells receiving no efflux buffer. *p<0.05 Basal + BIM versus Basal,
*p<0.05 MPP+ 20 µM versus Basal, ***p<0.001 MPP+ 60 µM and MPP+ 60 µM
+ BIM versus Basal, ***p<0.001 MPP+ 60 µM versus Basal + BIM, MPP+ 20
µM, MPP+ 20 µM + BIM, and MPP+ 60 µM + BIM. Statistical analyses were
performed by ANOVA with Tukey’s post hoc test of mean ± S.E. These results
indicate PKC activity contributes to the MPP+-stimulated DA efflux paradigm,
but may not be the sole contributor to this process.
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Figure 11. PKC inhibition reduces AMPH-stimulated DA efflux. LLCPK1
cells expressing wild type rat DAT were grown in 24-well plates and subjected
to the DA efflux assay. Efflux was induced by the addition of 37o KRH buffer
alone to determine basal or KRH containing 10 µM AMPH (n=6) and collected
5 minutes subsequently and assessed for radioactivity by scintillation counting.
Data are presented as % internal [3H]DA. 100% internal [3H]DA was determined
by lysing and assessing radioactive content of cells receiving no efflux buffer.
***p<0.001 Basal versus AMPH and AMPH + BIM, ***p<0.01 Basal + BIM
versus AMPH and AMPH + BIM, *p<0.05 AMPH + BIM versus AMPH.
Statistical analyses were performed by ANOVA with Tukey’s post hoc test of
mean ± S.E. These studies confirm PKC contributes to, but is not the only
mechanism by which AMPH-induced DA efflux occurs.
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(p<0.001 versus Basal), it did greatly reduce 60 µM MPP+-induced efflux (p<0.001
MPP+ 60 µM + BIM versus MPP+ 60 µM). This same pattern was achieved by
AMPH-induced DA efflux (Figure 11). AMPH stimulation was significantly curtailed
by PKC inhibition (p<0.001 AMPH + BIM versus AMPH). These experiments reveal
that MPP+ stimulation of DA efflux utilizes at least one mechanism in common with
AMPH, PKC activity, and perhaps, like AMPH, operates through additional
mechanisms to induce DA efflux.
Neurotoxin Effect on DAT Phosphorylation
To further understand the forward and reverse DA transport effects induced
upon neurotoxin-exposed DATs, we assessed the effect of MPP+ and 6-OHDA on
two prominent DAT post-translational modifications – phosphorylation and
palmitoylation. Neurotoxin-induced DAT phosphorylation was assessed by
radiolabeling with [32P] metabolically incorporated by kinase activity into rDATs
expressed in LLCPK1 cells (Figure 12). These cells were treated with neurotoxins
for 30 minutes with or without 200 nM PMA during which [32P] incorporation was
conducted. Equal amounts of radiolabeled DATs were immunoprecipitated with a
poly16 crosslinked protein A sepharose column, subjected to SDS-PAGE and
autoradiography. This signal was then normalized to equal amounts of rDAT
immunoblotted with MAb16 (Figure 13). Intriguingly, 6-OHDA significantly reduced
both basal (p<0.01 6-OHDA versus Control) and PMA-stimulated (p<0.01 6-OHDA
+ PMA versus Control + PMA) [32P]phosphorylation of rDAT relative to control in
each condition in this expression system. This suggests the attenuated DA efflux
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Figure 12. 6-OHDA inhibits basal and attenuates PMA-induced DAT
phosphorylation. rDAT-LLCPK1 cells labeled with 32PO4 were treated with
vehicle, 1 mM 6-OHDA or 1 mM MPP+ for 30 min at 37°C. Vehicle or PMA
treatment was conducted in parallel wells during the same incubation period.
(Upper Panel) Representative autoradiogram of poly 16 immunoprecipitated
32PO -labeled DATs. (Lower Panel) Quantification of 32PO -labeled DAT band
4
4
intensities from three independent experiments, **p< 0.01 (student’s t-test).
Foster and Vaughan, unpublished observation. These results indicate one
means by which 6-OHDA induces attenuation of DA efflux may be by inhibiting
transporter phosphorylation. Also, MPP+ generates DA efflux without altering
DAT phosphorylation.
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Figure 13. Total DAT protein expression is unchanged after neurotoxin
treatment. (Upper Panel) Representative immunoblot showing DAT protein
levels in sample lysates from [32P] labeling experiments. (Lower Panel)
Quantification of DAT content in rDAT-LLCPK1 cell lysates labeled with 32PO4;
three independent experiments. These results demonstrate neurotoxin
treatment does not induce loss of total transprter expression. Foster and
Vaughan, unpublished finding.
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effect generated by 6-OHDA upon DATs may involve blunting of DAT
phosphorylation mechanisms. Also surprising was the discovery that MPP+
application does not affect basal (p>0.05 MPP+ versus Basal) or PMA-stimulated
(p>0.05 MPP+ +PMA versus Basal + PMA) transporter phosphorylation, which is
crucial for AMPH-stimulated DA efflux. This implies the drug induces carriermediated DA efflux through mechanisms other than direct transporter
phosphorylation, and the BIM-attenuated DA release occurs through inhibiting
PKC phosphorylation of DAT-interacting proteins. The neurotoxin treatments were
shown to alter DAT phosphorylation characteristics without altering total DAT
protein levels (Figure 13).
Neurotoxin Effect on DAT Palmitoylation
As DAT palmitoylation plays a role in the protein’s DA uptake stability344,347
and is an additional mechanism involved in DAT-mediated DA efflux (Chapter 1),
DAT palmitoylation was analyzed after neurotoxin treatment to discern if these
compounds generate changes in this modification of DAT (Figure 14). To assess
transporter palmitoylation alterations resultant from 6-OHDA or MPP+ treatment,
rDAT-LLCPK1 cells were pretreated for one hour with IC50 concentrations of both
neurotoxins after which membrane preparations were performed and acyl-biotinyl
exchange (ABE) analysis was conducted. The ABE inquiry demonstrated these
neurotoxins have no effect on rDAT palmitoylation at the concentration and time
used. Perhaps longer treatment times will produce DAT palmitoylation changes,
but their acute effects generated on DAT forward and reverse DA transport is
independent of DAT palmitoylation modulation. At a 1 hour and 400 nM treatment
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Figure 14. Neurotoxin effect on DAT palmitoylation. Membranes isolated
from rDAT-LLCPK1 cells treated with vehicle, 400 nM PMA, 1 mM 6-OHDA,
or 60 µM MPP+ for 1 hr at 37o C were subjected to ABE. Hydroxylamine
(NH2OH) removes palmitate and enables the subsequent binding of the
sulfhydryl-specific HPDP-biotin thereby allowing for detection of
palmitoylated protein via NeutrAvidin chromatography and western blotting
(upper left panel). Band intensities from these blots are quantified and
normalized to their corresponding total immunoblotted DAT signals shown in
the lower panel. Statistical analysis was performed by ANOVA with Tukey’s
post hoc test p>0.05, n=3.
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paradigm, PMA also failed to reduce DAT palmitoylation. The concentration was
chosen as it was used in the preceding experiments despite 1 µM being previously
demonstrated to significantly reduce DAT palmitoylation 347.
Discussion
The neuronal expression of DAT is strongly positively correlated with
susceptibility of the neuron to death in the etiology and progression of PD 449–453;
as such, the aim of this study was to discern any DAT-specific effects produced by
the PD-inducing neurotoxins, 6-OHDA and MPP+, widely used in the medical
science research of this disease. The experiments were conducted in the LLCPK1
cell system stably expressing DATs. Competitive uptake assays (Figure 3)
determined that 6-OHDA and MPP+ do compete for the transporter DA
translocation site in this system and that their IC50 concentrations for it are 1 mM
and 60 µM respectively. Figures 4 and 5 represent experiments performed which
demonstrate these compounds downregulate DAT function and that their down
regulatory effects are DAT-mediated transport dependent. The next set of results
decisively confirm that MPP+ is an inducer of DA efflux at both 20 (Figure 6) and
60 µM (Figure 7) concentrations from rDAT, an effect which is contributed to by
functional PKC (Figure 10), and at 60 µM with hDAT (Figure 8). MPP+ was
previously discovered to dramatically increase extracellular DA levels when
perfused into the striatum480 and this release was DAT-dependent476, so the finding
that 6-OHDA reduces DA efflux, though not significantly, from rDAT-LLCPK1 cells
(Figures 6 & 7), and significantly form hDAT-LLCPK1 cells (Figure 8) is rather
interesting and reveals a striking difference between the mechanisms by which
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these two compounds operate. This 6-OHDA-reduced DA efflux effect was further
blunted by BIM inhibition of PKC (Figure 9), though this may be due to unstimulated
release being reduced by the same inhibitor (Figure 9). Though these compounds
produced no change in transporter expression (Figure 13) or palmitoylation levels
(Figure 14), 6-OHDA, interestingly, blunted basal and PMA-stimulated transporter
phosphorylation (Figure 12). This may explain the attenuation of reverse DA
transport by 6-OHDA, though the 5 minute exposure to the drug during the efflux
protocol may not allow enough time for the reversal of transporter phosphorylation
to occur as the phosphorylation (Figure 12) was assessed after a 30 min drug
exposure. To our knowledge, this is the first time a DAT substrate has been
demonstrated to blunt both DA efflux and DAT phosphorylation. MPP+ altered
neither DAT phosphorylation (Figure 12), DAT expression (Figure 13), nor DAT
palmitoylation (Figure 14).
As seen in Figures 2 and 3, pretreatment of DAT-expressing cells with the
PD-inducing neurotoxic DAT substrates downregulated DAT-mediated DA uptake
activity – MPP+ to a greater extent than 6-OHDA (Figures 4 & 5). These results are
consistent with the general behavior of DAT function after exposure to its
substrates for the time used in these experiments (30 min); that is to say, DATconducted transport of substrate (DA, AMPH, or methamphetamine) across the
plasma membrane reduces the capacity of the same DAT population to translocate
subsequent substrate220,481–486. This effect, however, occurs after substrate
exposure times greater than 1 min, before this point substrates rapidly recruit
transporter copies from endosomal pools to the plasma membrane 487, acutely
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increasing DA uptake capacity.

Depending on the study, the substrate-induced

downregulation of DAT activity has been shown to be one484,488 or a
combination483,486 of transporter internalization and PKC activity, and depends on
substrate species482,485,489. Interestingly, substrate exposure induces this DAT
uptake attenuation upon dorsal striatal DATs and not nucleus accumbens
DATs481,483,485, suggesting a cellular environment sensitive to DAT substrates in
dorsal striatal neurons and absent in accumbens neurons which responds to
transporter activity or cytosolic substrate to shut down DAT function. These could
be an outcome of divergent post-translational modification, endocytic, or
antioxidant mechanisms. It may be one of these systems which responds
differently to DAT or cytosolic chemistries instigated by 6-OHDA or MPP+ to
produce their contrasting effects on DAT activity. Transporter surface population
alterations need to be assessed to determine whether the observed toxin-induced
DA uptake downregulation results from a loss of plasma membrane protein or
other DAT-intrinsic or cellular environment factors.
Perhaps the most intriguing results from this study surround the DA efflux
investigations and reveal further differences between the actions of 6-OHDA and
MPP+ (Figures 6-11). MPP+ acts as a DA efflux enhancer while 6-OHDA is a DA
efflux reducer. The efflux response to MPP+, like AMPH, was blunted after PKC
inhibition though not abolished. This suggests that MPP+ and AMPH utilize PKC
activity to prompt DAT-mediated DA efflux in a similar manner. That MPP+476,490,491
and AMPH492,493 also act as substrates for the vesicular monoamine transporter 2
(VMAT2)239,240 further supports these molecules sharing similar DA-efflux inducing
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identities. These VMAT2 substrates empty vesicles of sequestered transmitter to
elevate cytosolic DA concentration, a process associated with degeneration of the
nigrostriatal DA tract494, perhaps by increasing the likelihood of DA-derivative
reactive oxygen species toxicity and/or enhancing DAT-facilitated DA efflux
causing a perturbed synaptic DA homeostasis. 6-OHDA reduction of carriermediated reverse DA transport renders this compound unique amongst DAT
substrates. The mechanism by which this occurs may involve oxidation damage to
important protein actors to the efflux schema, or its direct modification of DAT
which biases the transporter in an efflux-unfavorable conformation. PKC may be a
target of 6-OHDA activity which may be the mechanism by which 6-OHDA
attenuates basal and PKC-stimulated transporter phosphorylation, which, in turn,
would ablate DA efflux.
The neurotoxic effects on the DAT phosphorylation (Figure 12) and
palmitoylation (Figure 13) post-translational processes illuminated a potential
mechanism by which one of the studied compounds may alter DA efflux. Increased
transporter phosphorylation is classically identified with increased DA efflux
capacity229,

and,

therefore,

compounds

which

can

reduce

transporter

phosphorylation, like 6-OHDA, can conceivably reduce transporter-mediated
efflux. That MPP+ did not increase basal or PMA-stimulated DAT phosphorylation
may be due to low stoichiometric abundance of the induced phosphorylation event
which cannot be distinguished by the methodology used, especially in the PMA
background. The BIM-induced reduction of MPP+-stimulated DA efflux may be a
result of losing off target PKC and DAT interactors whose interplay is supported by
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MPP+ action rather than a loss of direct MPP+-triggered DAT phosphorylation.
Neither 6-OHDA nor MPP+ attenuated DAT palmitoylation which may be a result
of insufficient toxin exposure time or DAT palmitoylation being insensitive to these
compounds. As there is a reciprocal relationship between DAT phosphorylation
and palmitoylation347, 6-OHDA may generate increased transporter acylation after
longer drug incubation periods.
As stated previously, an anomalous DA efflux phenotype has been linked
to patients diagnosed with ADHD380 and early onset PD256. This DA efflux event is
now linked to disease etiology, drug rewarding and abuse properties226,495, and an
additional potential mechanism by which PD can be induced after MPP+ exposure.
DAT-mediated DA efflux does not only occur at perisynaptic DATs; indeed,
dopaminergic neuronal dendrites form dendro-dendritic synapses in the substantia
nigra496,497, and DA release at these synapses was proposed as a mechanism by
which these neurons can self-inhibit498,499. A seminal study500 elucidated the
mechanism by which this auto-inhibitory process occurs: DAT-mediated DA efflux
at dendro-dendritic synapses. MPP+-produced DA efflux at this locus would likely
induce the same auto-inhibitory effect on the nigro-striatal dopaminergic nerve
cluster; perhaps stimulation of DA release by MPP+ contributes to this drug’s
neurotoxic profile. This substantia nigra dendritic DA release is likewise elicited by
AMPH treatment498,501. Taken further, both METH and AMPH use is associated
with PD502–504, and a similar study observed an increased risk for PD amongst
users of AMPH and METH but not cocaine505. These studies, along with the MPP+
DA efflux data presented herein, suggest induction of DA efflux at dendro-dendritic
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synapses of the substantia nigra as a mechanism by which loss of the nigrostriatal
DAergic tract, witnessed in PD, can be exacerbated. An antidote to this flux
problem may be derived from uncovering the mechanisms by which 6-OHDA
blunts DAT-mediated DA release, as one of them may reveal a novel therapeutic
input point at which aberrant DA efflux-associated diseases can be alleviated.
Perhaps this input point can remain DAT if a high-affinity DAT substrate can be
synthesized which mimics the properties of 6-OHDA which enable it to dampen
DAT-mediated DA efflux (conceivably, one such property is reducing DAT
phosphorylation) without the properties which cause massive oxidative damage.
Methods
Cell Culture
LLCPK1420 cells stably expressing WT or mutant rDATs were grown in
Dulbecco’s Modified Eagle Medium (DMEM) containing 5% fetal bovine serum,
100 µg/mL penicillin/streptomycin, and supplemented with 400 µg/mL of the
selection reagent Geneticin (G418) for stably expressing cell lines. Cells were
maintained in a humidified incubator with 5% CO2 at 37oC.
Generation of DAT-Expressing LLCPK1 Cells
For generation of cell lines stably expressing WT hDAT or rDAT cDNA
constructs421, LLCPK1 parental cells were seeded into 12-well plates and grown to
~50% confluence. At this point the cells were transfected. X-tremGENE
transfection reagent was mixed with plasmid DNA (1.4 µg of DNA/well of a 12-well
plate) at a reagent:DNA ratio of 3:2 in OptiMEM for 20 min at ambient temperature
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after which the transfection complex was added to each well and transfection
proceeded for ~36 hours. The cells were then transferred to a culture flask to
undergo selection of expressing cells via 800 µg/mL G418 treatment. After two
subculture passages at this G418 concentration, the cells were collected, the
plasma membranes were harvested, and expression of r or hDAT was analyzed
by immunoblotting with the anti-DAT mouse monoclonal antibody MAb16. If the
transfection was successful, the stably expressing rDAT cells were maintained in
400 µg/mL of G418 for all subsequent uses.
SDS-PAGE and Western Blotting
DAT proteins and peptides were denatured in Laemmli sample buffer (SB:
125 mM Tris-HCl, 20% glycerol, 4% SDS, 200 mM DTT, 0.005% bromophenol
blue) and were electrophoretically resolved using 4-20% polyacrylamide gels
alongside a ColorBurst protein standard. Proteins were then transferred to a
transfer buffer (25 mM Tris-HCl, 192 mM Glycine, 0.1% SDS, 10% methanol) equilibrated polyvinylidene fluoride (PVDF) membrane after which blocking was
performed with a 3% BSA/PBS buffer. Primary MAb16 antibody was diluted
1:1,000 in the blocking solution and the blocked PVDF membrane was incubated
in this antibody solution for 1 hour at ambient temperature. After five washes the
membrane was incubated in alkaline phosphatase (AP)-linked anti-mouse IgG
secondary antibody diluted to a 1:5,000 ratio in blocking buffer for 1 hour followed
by 5 additional washes. 3 mL of Immun-Star™ AP substrate (Bio-Rad) was applied
to the membrane and incubation proceeded for 5 min at ambient temperature.
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Generated chemiluminescent Western blot band intensities were quantified using
Quantity One® software (Bio-Rad).
Neurotoxin Dose-Response Assay on Inhibition of DA Uptake
WT rDAT LLCPK1 cells were seeded in 24-well assay plates and grown to
~80% confluence. Immediately preceding the assay, serial dilutions of 6-OHDA
(final reaction concentrations of 1 x 10-5, 1 x 10-4, 1 x 10-3, 1 x 10-2, and 3 x 10-2)
and MPP+ (final reaction concentrations of 1 x 10-7, 1 x 10-6-, 1 x 10-5-, 1 x 10-4, and
1 x 10-3) in 150 µL of Krebs Ringer/HEPES buffer (KRH, 25 mM HEPES, 125 mM
NaCl, 2.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 5.6 mM glucose, 1.3 mM
CaCl2) containing 25 µM DA. The cells were washed with 37oC KRH after which
500 µL of 37oC KRH was added to each well. Assay plates were placed in a rocking
water bath at 37oC. DA uptake was initiated by addition of 10 µL of the appropriate
neurotoxin/DA mixture to each well at timed intervals. The uptake reaction
proceeded for 8 minutes and was terminated by aspiration of the reaction mixture
and 2 washes of each well with ice-cold KRH. The cells were solubilized with 250
µL of Trition X-100 at ambient temperature for 30 minutes with gentle shaking. The
solubilized cells were collected in scintillation vials to which 3 mL of scintillation
fluid was added. Radioactivity was assayed by scintillation counting. The extent of
DA uptake inhibition was relative to uptake control wells which received no
neurotoxin inhibitor, and IC50 concentrations of each neurotoxin were determined
by nonlinear regression analysis (one site competitive binding).
DA Uptake Downregulation Assay
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WT rDAT-LLCPK1 cells were seeded in 24-well assay plates and grown to
~80% confluence. These cells were washed with 37°C KRH and subsequently
pretreated with vehicle, 400 nM PMA, 20 µM DA, 20 µM 6-OHDA, or 20 µM MPP+
in 500 µL KRH at 37°C and 5% CO2 for 30 min. The cells were then rapidly washed
with 4°C KRH three times prior to assay for DA uptake. DA uptake was induced by
addition of 10 µL of the DA reaction mixture (Final concentration of DA was 3 µM)
at timed intervals. DA uptake continued for 8 minutes and was terminated by
removal of reaction buffer and well washout with 1 mL of ice-cold KRH. The cells
were solubilized with 250 µL Trition X-100 for 30 minutes at ambient temperature
and gentle rocking. Cell lysate was collected into scintillation vials and radioactive
content was determined by scintillation counting. DA uptake downregulation is
expressed as the percentage of DA uptake loss compared to untreated control
cells.
Neurotoxin Pre-Incubation DA Uptake Assay
24-well plates grown to ~80%-90% confluence with LLCPK1 rDAT or hDAT
cells were washed with 0.5 mL 37oC KRH buffer and resupplied with KRH buffer
with or without 400 nM PMA, 20 µM DA, 20 µM 6-OHDA, or 20 µM MPP+ for 30
min at 37oC and 5% CO2. These same concentrations were incubated in the
presence of 100 µM cocaine for the DAT uptake control conditions, also for 30 min
at 37oC and 5% CO2. After the substrate incubation, DA uptake was conducted for
8 min at 37oC with 3 µM total DA containing 10 nM [3H]DA. Excess DA was rapidly
washed out with KRH buffer and the cells were lysed by incubation with 250 µL
1% Tx-100 for 20 min at ambient temperature. The lysates were collected and
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analyzed for [3H] content by liquid scintillation counting. Neurotoxin uptake data
are presented as % uptake control. The cocaine-treated conditions were compared
to the cocaine control conditions.
Neurotoxin DA Efflux Assay
Stably expressing WT hDAT or rDAT-expressing LLCPK1 cells were grown
in 24-well assay plates to ~80% confluence. Cells were loaded via DA DATmediated uptake of 3 µM DA containing 10 nM [3H]DA for 30 minutes in 37oC KRH.
Extracellular DA was rapidly washed out 3 times with 4oC KRH on ice, and the
assay plate was transferred back to the water bath and 37oC KRH efflux buffer
with KRH alone, 10 µM AMPH, or the indicated neurotoxin concentration was
rapidly added to avoid cell drying and rupture upon buffer addition. The efflux buffer
was collected after five minutes and analyzed for radioactive content; one column
of cell wells received no efflux buffer and was lysed by incubation with 1% Triton
X-100 for 20 min at ambient temperature and served as the total internal [ 3H]DA
control and was analyzed in parallel for [3H] content by liquid scintillation counting.
The efflux values are expressed as a percent of the total intracellular [ 3H]DA. For
the PKC inhibition DA efflux experiments, cells were incubated with 10 µM
Bisindolylmaleimide (BIM) in KRH during the 30 min load portion of the experiment.
Dopamine Transporter Phosphorylation Assay
WT rDAT LLCPK1 cells were grown to 80% confluence in 6-well assay plates.
Once desired confluence was achieved, cell medium was replaced with PO 4-free
medium and incubated for 1 hour at 37oC and 5% CO2. 10 µL of 32PO4-containing
medium was then added to each well (final radioactivity concentration: 0.5
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mCi/mL). This incubation proceeded for 2 hours after which 1mM of each
neurotoxic compound was added for 30 minutes with or without the transporter
phosphorylation-stimulating 200 nM PMA positive control. Cells were washed
three times with ice-cold Buffer B (0.25 mM Sucrose, 10 mM triethanolamine, and
pH was adjusted to 7.8 with 100 mM acetic acid), scraped, and collected in
separate microfuge tubes. The collected cells were centrifuged at 2,000 xg for 5
min at 4oC and supernatants were discarded. Cell lysis was produced by
resuspension and nutation of pellet in 750 µL lysis buffer (10 mM triethanolamine
pH 7.8, 2 mM ethylenediaminetetraacetic acid [EDTA], 150 mM NaCl, and 0.1%
Triton X-100 containing 100 mM DTT and protease inhibitor cocktail) for 10
minutes at 4oC. This was followed by centrifugation of samples at 4,000 x g for 5
minutes. The supernatants were transferred to fresh microfuge tubes and 200 µL
of 2% SDS (0.5% final concentration) was added and vortexed well. These
samples were subjected to a final centrifugation at 20,000 x g for 30 minutes at
4oC. 900 µL of the supernatant fraction was collected from which 25 µL was
analyzed by Western blotting to ascertain DAT levels. Equal DAT protein from
each sample (200 µL, or adjusted to 200 µL with lysis buffer) was isolated by
immunoprecipitation with protein A cross-linked to the rDAT-reactive poly-16
antibody in immunoprecipitation buffer (IPB, 50 mM Tris, 0.1% Triton X-100, pH
8.0) for 2 hours at 4oC with nutation. The column was washed 4 times with IPB
containing 0.1% SDS at ambient temperature and DAT was eluted with 35 µL of
1x sample buffer. Samples were subjected to SDS-PAGE for 1 hour 45 minutes at
150 V and 35 mA in a 4-20% polyacrylamide gradient gel. The gels were dried and
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radioactive

content was assessed by autoradiography.

Autoradiography

signatures were normalized to equal, immunoblotted DATs from each sample and
data are presented as % basal DAT phosphorylation.
Plasma Membrane Preparation
WT rDAT-LLCPK1 cells were grown in 150 mm plates to ~80% confluence.
400 nM PMA, 1 mM 6-OHDA, or 60 µM MPP+ in KRH or KRH alone was applied
to two plates each for 1 hour at 37oC and 5% CO2. After treatment, cells were
washed twice with Buffer B, scraped, and collected in Buffer B containing a
protease inhibitor cocktail of 1 µM phenylmethylsulfonyl fluoride (PMSF) and 5 µM
EDTA at 4oC. Cells were then pelleted via centrifugation at 3,000 x g for 5 min at
4oC, supernatants were removed, and the cell pellets were suspended in Buffer C
(0.25 M sucrose, 10 mM triethanolamine, 1 mM EDTA, and the pH was adjusted
to 7.8 with 100 mM acetic acid) and subsequently homogenized using a Dounce
homogenizer. Cellular debris and nuclei were cleared from the homogenates by
centrifugation at 800 x g for 10 min. The post-nuclear supernatant was collected
and centrifuged at 18,000 x g for 12 min, and the resulting plasma membrane pellet
was suspended in sucrose phosphate (SP) buffer (10 mM dibasic sodium
phosphate, 0.32 M sucrose, pH 7.4 with 1 µM PMSF and 5 µM EDTA).
Acyl-Biotinyl Exchange
This ABE method was adapted from Wan et al341 where detection of
palmitoylated proteins are described in three steps: Free cysteine thiols are
blocked; thioester linked palmitoyl groups are specifically removed by
hydroxylamine (NH2OH); and the previously palmitoylated and now free sulfhydryl
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groups are biotinylated. Plasma membranes isolated from control, PMA, or
neurotoxin-treated WT rDAT LLCPK1 cells were solubilized in 250 µL of ABE lysis
buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing protease
inhibitor and 20 mM methyl methanethiosulfonate (MMTS) to react with unbound
Cys sulfhydryl moieties and incubated for one hour at ambient temperature. MMTS
was removed by a 1 mL acetone precipitation and centrifugation at 18,000 x g for
10 min. The pellet was dissolved in 250 µL 4SB ABE buffer (50 mM Tris, 5 mM
EDTA, 4% SDS, pH 7.4) and remnant MMTS was removed by an additional 1 mL
acetone precipitation and centrifugation. The pellet was then subjected to a further
acetone wash. The pellet was suspended in 200 µL 4SB buffer and thioesterified
palmitate molecules were specifically removed by hydroxylamine (NH2OH); The
sample was split equally (100 µL) into negative control (800 µL, 50 mM Tristreated) and NH2OH-treated (1.4 mM) halves and incubated at ambient
temperature for 30 min with end-over-end mixing. The free sulfhydryl groups were
reacted with 100 µL (0.4 mM final concentration) of a sulfhydryl-specific
biotinylating reagent, HPDP-biotin in the Tris or NH2OH mixtures. The now HPDPbiotin-containing samples were incubated for 3 min in a 37 oC water bath then at
ambient temperature for 1 hour. Excess NH2OH and biotin reagents were removed
by the 4:1 acetone to sample volume precipitation, centrifugation at 18,000 x g,
supernatant aspiration, 250 µL 4SB pellet suspension, 1 mL acetone precipitation,
centrifugation at 18,000 x g, supernatant aspiration, 1 mL acetone wash,
centrifugation at 18,000 x g, and supernatant aspiration workflow. The final pellet
was suspended in 75 µL ABE lysis buffer and 10 µL of this was set aside for total
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DAT immunoblotting while 65 µL was added to 50 µL of a 50%

slurry of

Neutravidin resin in 1500 µL Tris buffer to affinity purify the biotinylated proteins or
peptides overnight at 4oC with nutation. Unbound peptides were washed away by
three

cycles

of

8,000

x

g

centrifugation

and

900

µL

radioactive

immunoprecipitation assay buffer (RIPA: 1% Tx-100, 1% sodium deoxycholate,
0.1% SDS, 125 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM NaF).
Proteins and peptides were eluted from the final pellet by incubation in 2x Laemmli
SB for 20 min at ambient temperature. Samples were then subjected to SDSPAGE, and immunoblotted with mouse anti-rDAT primary antibody (MAb16).
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CHAPTER 4
DISCUSSION
Limitations of the Work Presented in this Dissertation
Many of the data presented are from analysis of mutation of the putative
palmitoylation sites. As such, the presented data may be a result of the amino acid
substitution rather than loss of palmitoylation of that residue.
The main drawback of the ABE method is that the assay is susceptible to
capture of proteins which are modified through thioester bonds between Cys
residues and modifying groups other than a fatty acid. If the protein of interest
forms non S-palmitoylation thioester bonds it will be picked up as a false positive
for S-palmitoylation by ABE. Examples of other post-translational modifications
that form thioester bonds include S-acetylation, which is supported by surrounding
basic residues like the situation with DAT Cys6, the phosphopantetheine prosthetic
group’s sulfhydryl modifying an interacting protein’s Ser hydroxyl, and acyl-CoA
substrates506–508. The ABE method is unable to detect multiple modification events
on poly-palmitoylated proteins which the acyl-PEG exchange (APE) method is able
to do by incorporation of maleimides of known Mr into the protein which can be
visualized by multiple upward band shifts in a Western blot corresponding to the
number of the protein’s acylation sites509.
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The biochemical efflux assay used throughout this dissertation relies on
expressed DAT to transport extracellularly-applied [3H]DA into the cell to supply
the efflux-ready substrate pool. The act of transporting DA induces transporter
downregulation481–485 which likely affects DA efflux capacity as well as AMPH
interaction with DAT. Scintillation counting of the radiolabeled DA, though
quantitative, does not represent a 1:1 ratio of counted DA to effluxed DA. This
assay can only be performed on heterologous expression systems or immediately
after tissue excision.
The majority of experiments in this dissertation were performed on DATexpressing cells and ought to be confirmed in endogenous tissue.
Future Studies
The APE method should be optimized for endogenous rDAT to confirm the
number of S-palmitoylation sites. This will be difficult as one needs a large Mr
maleimide linker to produce distinguishable DAT bands as it produces a thick, ~80
kDa Western blot signature. [3H]palmitic acid labeling of WT NDAT, Cys6Ala
NDAT, and Cys90Ala rDAT could be performed to confirm that modification of
Cys6 and Cys90 is actually a palmitoylation event as opposed to an alternative
thioester-based modification. To assess the 2BP-induced and Cys mutant DAT
conformational alterations, binding assays of the high affinity cocaine analog [3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane)

can

be

implemented.

The

contribution of global palmitoylation (using 2BP) and the novel DAT palmitoylation
sites to DAT downregulation can be analyzed by PMA treatment and DA uptake
assays. The test if PIP2 and cholesterol-DAT interactions are supported by
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palmitoylation events, PIP2 inhibition391 and cholesterol depletion156 can be used
to see if forward or reverse transport process are affected by these conditions.
Cys90Ala rDAT should be assessed by microscopy to determine if palmitoylation
of this residue suppresses surface transporter levels and increases endosomal
DAT content. All the experiments described in chapter 2 that can be applied to
Cys6/90/580Ala rDAT should be carried out. Time course neurotoxin treatment
should be implemented to assess whether 6-OHDA or MPP+ have any effect on
DAT palmitoylation and surface transporter expression. DAT palmitoylation
characteristic can be influenced to attempt to alleviate the anomalous DA efflux
phenotype of Ala559Val and other DAT single nucleotide polymorphisms
associated with disease.
Summary Conclusions
The first study strongly supports the existence of amino-terminal
palmitoylation. It indicts the residues Cys6 and Cys90 as the potential
palmitoylation sites in addition to Cys580. This study further concludes a Cys90
acylation event may suppress surface transporter expression and this residue is
important for maintaining DAT uptake Km for DA. Mutation of Cys6 to Ala
decreases basal and AMPH-stimulated DA efflux, and global palmitoylation
contributes to DA uptake stabilization and dampens DA efflux. Manipulation of DAT
palmitoylation status may be an avenue of approach to finer pharmaceutical
control over DAT activity.
The second study concluded 6-OHDA is a DAT substrate which blunts both
DA efflux and transporter phosphorylation, and MPP + downregulates DA uptake
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and strongly induces DA efflux. This study further implicates the DA efflux
phenomenon as contributing to PD pathology256, and warns against the use of
efflux-inducing DAT pharmacotherapies which predispose one to PD.
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